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Abstract 
Muscle mass declines 1-2% every year after the age of 50 years. Contractile forces by 
muscle exert strains on bone and influence the bone mass and strength. Not only is 
age a cause for muscle and bone decline, circulating factors can play a role, aiding the 
signalling between muscle and bone.  
Chapter 3 investigates exercise as a way in which we could reduce the loss of whole 
body bone mineral density (BMD) and muscle mass in older age. Included in this 
chapter were 38 master sprint runners (28 males, 10 females, mean age 71±7y), 149 
master endurance runners (111 males, 38 females, mean age 70±6y) and 59 non-
athletic controls (29 males, 30 females, mean age 74±5y). Sprinter hip BMD was 10% 
and 14% greater than that in endurance runners and controls respectively, but it was 
difficult to explain this increased BMD by accelerometry or differences in muscle 
strength. Following on from this, Chapter 4 highlights that there are circulating factors 
playing a role within the ageing skeleton. Factors dickkopf-1, osteocalcin, 
osteoprotegrin and sclerostin were identified to be positively associated with whole 
body bone mineral density in older adults (n=272), with multivariate regression 
showing body mass index, circulating sclerostin and whole-body lean mass together 
accounting for 13.8% of the variation with WBMD. 
To further investigate the circulating factors, statistical modelling was used to identify 
those which were also associated with whole body lean mass. Tumour necrosis factor 
alpha (TNF) and osteoprotegrin (OPG) were significantly negatively (r=-0.170, 
p=0.007) and positively associated (r=0.140, p=0.030), respectively, with whole body 
lean mass. With multivariate regression showing height and OPG to account for 45% of 
the WB Lean mass in older adults. These results, combined with Chapter 4, highlighted 
OPG as a key molecule associated with both bone and muscle during ageing. Using 
these findings, in Chapter 6 the interactions between TNF and OPG were modelled 
using human myoblast cells in vitro. From the investigations in vitro it was clear that 
OPG is capable of enhancing muscular growth and when incubated with TNF the 
myoblasts are able to secrete OPG, providing a protective mechanisms against TNF.  
The findings within this thesis can conclude that circulating factors, particularly OPG, 
are able to interact with muscle and bone and have an influence the decline during 
ageing. Exercise, particularly, sprinting can help reduce decline in bone health but 
circulating factors provide a new insight that could help our forever ageing population. 
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1.1. Chapter 1: Introduction 
Loss of muscle mass occurs progressively after 40 years and the resultant low muscle 
mass in older age is a recognized disease called sarcopenia [1]. Low muscle mass 
causes muscle weakness and since the contractile forces developed by muscle exert a 
strong influence on bone development and maintenance throughout the life span, it is 
likely that sarcopenia is related to osteoporosis, mainly affecting older adults. Muscle 
mass and strength decline by around 1-2% per year after 50 years [1]. Osteoporosis 
affects 3 million older people in the UK, arising as bone remodelling favours resorption 
of mineralised extracellular matrix over bone formation and increases fracture risk [2]. 
 
Evidence suggests that sarcopenic men have a 3-fold increased risk of osteoporosis 
compared with non-sarcopenic men [3], due in part to lower peak forces transmitted 
from muscle to bones during physical activities (known as the mechanostat theory) [4]. 
Despite this evidence from epidemiological surveys, older people with low muscle 
mass should not necessarily accept a future with osteoporosis and a high risk of bone 
fractures. Instead, it may be possible even for the small, weak muscles to transfer 
contractile forces with sufficient osteogenic potential to maintain bone health through 
highly repetitive eccentric muscular contractions [5]. Such activities would include 
regular sports training, particularly running or resistance exercises. There has been 
research to show that exercise during ageing can help slow the decline in bone health 
[6-8], but there has been very little research into this possibility within the sarcopenic 
population. There are studies on general older populations to show improvements in 
the rate muscle loss through exercise, which is discussed later in section 2.1.6. If it 
proves to be the case, then it will evidence a mechanism through which sarcopenic old 
may improve their bone health. 
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It is not only through the direct ‘impacts’ of muscle forces acting on bone that provide 
osteogenic stimuli: two-way exchange of circulating factors between muscle and bone 
can influence cellular signalling in the target tissue and direct growth and maintenance 
[9, 10]. For instance, bone regulatory factors and cytokines released from osteoblasts 
during bone formation and osteoclasts during bone resorption are abundant within 
the extra cellular fluid and enter the circulation where they come into contact with 
skeletal muscle fibres and satellite cells. These circulating bone regulatory factors have 
the potential to facilitate cross-talk between bone and muscle tissue, but there has 
been very little research into possible interactions [10]. Some of the candidate bone 
regulatory factors possibly related to BMD and acting on skeletal muscle includes: 
osteoprotegerin (OPG) and osteocalcin (OC) [11-13] which are secreted by osteoblasts 
for bone formation; dickkopf-1 (DKK1) [14] and sclerostin [15] are released by 
osteocytes, which negatively regulates bone formation. Additonally, osteopontin [16] 
(OPN) is another factor released by osteoblasts, osteocytes and osteoclasts to facilitate 
bone resorption. Tumour necrosis factor- alpha (TNFα) [17] is a pro-inflammatory 
cytokine, also implicated in bone and muscle remodelling and possibly involved in 
bone-muscle cross-talk. Very little is known about how these bone regulatory factors 
act on skeletal muscle and in particular how might this be affected by the process of 
ageing. 
 
The research completed as part of this PhD study will provide novel insights into the 
muscle and bone health of exceptionally athletic older adults compared with non-
athletic old and will investigate how circulating bone regulatory factors may influence 
the loss of muscle and bone with ageing. If specific exercise or molecular factors with 
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osteogenic and/or myogenic potential can be identified, it may lead to new 
therapeutic targets to help prevent muscle and bone loss in older age. 
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2.1. Chapter 2: Literature Review 
2.1.1 Ageing 
The number of people aged over 60 years is growing more rapidly than any other age 
group. It was estimated that there was 688 million 60 years and over in the year 2006 
and by 2050 this number is projected to grow to approximately two billion, with about 
20% of those being over 80 years old [2]. The increasing proportions of older people 
living in our communities is a positive reflection of health and social care advances, but 
there are also unintended negative consequences as health and physical function 
decline progressively in old age [2]. Consequently, older people are living for longer 
with long term conditions impacting negatively on their quality of life. Understanding 
and combating poor health is a public health priority in order to compress the period 
of later life spent with disability and to keep older people living independently in their 
own homes. 
 
Ageing results, as an accumulation over years, from a range of cell and molecular 
damage. As a result of this damage there is a decline in both mental and physical 
capacity leading to a greater risk of disease, with the ultimate consequence being 
death [18]. The deterioration over time will vary from person to person depending 
upon both genetic and environmental factors [19]. Ageing is considered one of the 
greatest risk factors for developing musculoskeletal, neurodegenerative and 
cardiovascular diseases [20]. There have been four main physiological processes 
identified to contribute to the ageing process at a cellular level; telomere shortening, 
mitochondrial dysfunction, oxidative stress and cell senescence [21]. Telomeres are 
repetitive DNA elements found at the end of chromosomes, their role in normal cell 
function is to protect the DNA ends from damage and degradation. With every cell 
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division telomeres shorten and eventually, as cells reach a certain age, the telomeres 
break and initiate cell apoptosis by activation of p53 tumor suppressor protein [22-26].  
 
Mitochondrial dysfunction and oxidative stress can influence one another. 
Mitochondria are the source of oxidative phosphorylation within cells. As cells age 
there is an increased amount of reactive oxygen species (ROS) due to continuous 
mitochondrial DNA damage. The ROS accumulation affects replication and 
transcription, leading to mutations of the mitochondria DNA, resulting in a further 
increase in ROS. In turn, this results in a decline in mitochondria function, further DNA 
damage and ROS production [27], a continuous cycle of damaging events. Thus, it has 
been deemed that ageing is partly due to an increased accumulation of mitochondrial 
DNA by the accumulation of ROS, resulting in a decline in respiratory function [28-31]. 
  
Senescence is a cell cycle arrest that is induced by certain stressors such as DNA 
damage. It is induced within replicative ageing of cells. These senescent cells then 
accumulate within tissues and contribute to the loss of functional ability and lack of 
regeneration, both associated with ageing [32]. Whilst within cell cycle arrest, the cells 
also secrete proteins known as senescence-associated secretory phenotype (SASP) 
[32]. The SASP’s disrupt normal homeostasis of the cells, preventing further 
proliferation, causing more cell death [33]. 
 
2.1.2 Ageing and bone tissue 
 
Bone makes up the skeletal system of vertebrates and is capable of adapting according 
to stresses it undergoes [4]. Its strength and volume adapt throughout life by 
continuous processes of bone formation and resorption. This bone tissue remodelling 
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is not maintained in the ageing bone microenvironment, as formation fails to keep 
pace with resorption [34, 35]. 
 
Throughout life, the primary functions of bone are; to provide attachments for muscle 
tendons and ligaments, to act as a nutrient reserve (particularly calcium), protect the 
organs and play a role in haematopoiesis [36]. Approximately 75% of bone is 
composed of compact/cortical bone mass and the remaining 25% is principally 
accounted for by the inner segment of the bone consisting of interconnecting spicules, 
forming the trabeculae. This type of bone is called cancellous bone, also known as 
trabecular bone. The structure of this section is adapted to its function by having a 
larger surface area allowing bone forming and resorbing cells to have greater chance 
to contact the bone surface more frequently [36]. The end of bones, known as the 
epiphysis, are predominantly trabecular bone. The mid shaft of the bones, known as 
the diaphysis, are much more dense and are predominantly cortical bone. Figure 2.1 
shows how the different types of bone are arranged within a typical long bone. 
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Fig 2.1; Long bone cross sectional view, showing the internal structure of the bone. Adapted 
from [37]. 
 
 
The mass of bone is maintained by the balances of two types of bone cells known as 
osteoclasts and osteoblasts. Osteoblasts are involved in formation of bone whilst 
osteoclasts are involved in bone resorption. The interaction of osteoblasts and 
osteoclasts at the bone surface are demonstrated in figure 2.2. Osteoclasts are derived 
from haemopoietic stem cells. The osteoblast cells are derived from mesenchymal 
stem cells along with stromal and bone lining cells. For a steady state of bone 
homeostasis, it is important that the balance between osteoblasts and osteoclast 
action are maintained. Bone resorption occurs at a much higher rate than does bone 
formation, a small increase, hence an imbalance of the action, in osteoclasts could 
then cause bone loss [36, 38]. Bone resorption by osteoclasts takes just 30 days and 
the bone remodelling cycle takes 3 months [38].  
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Figure 2.2; An example of the interactions between osteoblasts and osteoclasts involved in bone 
remodelling processes. Adapted from [38] 
 
The majority of bone mass is accumulated by the age of 20 years old [39]. 
Approximately 26% of resultant adult bone mass is accumulated during the final two 
years surrounding peak bone growth velocity, which approximates the amount of bone 
lost, later in life, during post-menopausal years, for women in particular [39-42]. Males 
usually have a greater BMD than females, as shown in twin studies [43], the decline in 
BMD starts at different time points for males and females. For males, the decrease 
begins around the age of 40 and females, around the age of 30 years [44]. 
 
Ageing is associated with a loss of bone mass and strength [45] due to a greater rate of 
resorption (via osteoclasts) than formation (via osteoblasts), and a reduction in the 
force of muscle contractions. Ageing bone can also be influenced by increased free 
radicals as a result of oxidative stress [46], in particular advanced oxidative protein 
products [47] which have been shown to be negatively correlated with femoral BMD. 
Another study has highlighted hydrogen peroxide (H2O2) or xanthine/xanthine oxidase 
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(XO), as free radicals, which resulted in inhibition of differentiation markers in the 
bone osteoblastic cells, MC3T3-E1, as well as the marrow stromal cells, M2-10B4, 
whilst leading to increased oxidative stress [48]. 
 
Within a clinical setting this age-related decline may be identified by a reduction in 
BMD and/or an increased rate of bone fracture. As the skeleton naturally reduces in 
strength and density over time, it is more likely to succumb to the skeletal disease, 
Osteoporosis, which is often associated with menopause and ageing. Osteoporosis is 
characterized by low bone mass along with ‘micro architectural’ deterioration of bone 
tissue which increases the fragility of the skeleton and, therefore, the increased 
likelihood of a fracture [49]. Osteoporosis arises as the balance of bone remodelling 
favours resorption of mineralised extracellular matrix over formation [2]. It affects 
around 3 million people in the UK alone [2, 50]. The main problem of Primary 
Osteoporosis is the continued breakdown of trabeculae structure within the bone. For 
females, post-menopause, there is a significant decline in oestrogen availability, 
contributing to the decline in BMD with age. For ageing males, sex hormone binding 
globulin has the ability to inactivate testosterone and oestrogen, also contributing to 
the decline in BMD [51-54]. Secondary Osteoporosis arises due to co morbidities or 
disease such as Cushing syndrome [55] and long-term glucocorticoid therapy [56]. Life 
style factors such as poor diet, particularly low in calcium, under nourishment, 
smoking and excessive alcohol are all detrimental to bone health [51, 57]. 
Osteoporosis was defined using the T-Score, which is a measurement of bone density 
in g.cm2 compared to a bone density measurement of a healthy 30-year-old adult of 
the same sex. Osteoporosis is classed as 2.5 standard deviations below the T score, 
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typically using sites of the hip, spine or forearm [58]. Within research Z-scores tend to 
be used which are similar measures to that of the T score, except the Z score is 
compared to an age matched person, rather than a 30 year old adult. In 1994 it was 
identified by the World Health Organisation (WHO) as an established, defined disease 
affecting more than 75 million people across Europe, Japan and the US [59]. Currently 
the assessment of bone mineral density (BMD) by dual X-ray absorptiometry (DXA) is 
the preferred measurement available in a clinical setting [59] and osteoporosis usually 
remains undiagnosed until a fracture arises and imaging is subsequently performed 
[60]. The hip and lumbar spine are sites most likely to experience the most severe 
effects of osteoporosis due to the quantity of trabecular bone within the vertebral 
bones [58], and the hip being the initial point of impact if a person falls sideways [58]. 
However, when imaging these areas other factors such as scoliosis, calcification and 
vertebral fractures may impair the ability to diagnose osteoporosis [58, 59]. To that 
end, more recently, the osteoporosis diagnosing criteria has changed to use the 
femoral neck only, along with an international reference standard per age, using the 
same reference for both men and women. This is deemed suitable as the risk of 
fracture at the femoral neck at any age is similar in men and women [59, 61-64]. 
Another imaging technique used to assess bone health is peripheral quantitative 
computed tomography (pQCT). Using pQCT, the inner structure of the bone can be 
assessed, as shown in several studies [7, 8, 65], comparatively to just the aerial view of 
the bone as seen in DXA imaging. However, pQCT can only be applied to the limbs and 
it is not able to assess the bone mass or geometry of the hip and spine, which are the 
main sites affected by osteoporosis in older age. 
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Falls are also more likely to occur in older age, [66, 67]. This, combined with a weaker 
skeleton, predisposes the old to an increased fracture rate. Hip fractures in particular 
are associated with a high mortality rate [53, 58, 62] and are a significant cost to the 
current national health service [58, 59]. In 2010, within Europe, it was estimated that 
the cost of fragility fractures, was 37 billion Euros. Of this cost, 66% attributed to 
incidents, 29% for fracture care and just 5% on pharmacological interventions [59, 68]. 
This total cost is expected to increase 25% by the year 2025 [59, 68]. 
 
There are both non-pharmacological and pharmacological treatments suggested to 
help management of osteoporosis [60]. In the early stages of the disease, non-
pharmacological interventions are recommended, such as increasing dietary calcium 
and vitamin D intakes, 1000-1200mg of calcium is the current recommended daily 
intake for elderly men and women [69]. Along with smoking cessation, the limitation of 
alcohol consumption and increasing weight-bearing exercises [69-72].  Weight bearing 
exercises are discussed later in this thesis. Pharmacological therapy is usually 
prescribed following a fracture, aimed at reducing the likelihood of any further 
fractures. These medications are usually anti-resorptive, decreasing the rate of bone 
resorption such as bisphosphonates, or others are anabolic, which increase bone 
formation, such as teriparatide [69, 73]. Long term use of these drugs does come with 
potential side effects, such as acid reflux, gastrointestinal problems, poor renal 
function, jaw necrosis which affects approximately 1 in 10,000 [74], and 
osteosarcomas [75]. The rate of osteosarcomas is relatively low, with 2 out of 430,000 
patients presenting in 2009  [69, 75]. Alternative ways of managing osteoporosis are 
always being investigated. 
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2.1.3 Exercise and Bone  
Strains the bone receives during exercise are compression, tensile and torsional forces 
as well as shear stress. All these strains and stresses can be applied to the same bone 
at the same time during exercise. The specific strain and amount of strain that is 
needed to stimulate bone remodelling is still yet to be defined, as is the specific 
recommendations of type and duration of exercise in ageing needed to maintain bone 
health [76].  
Exercise across the life course can help to prevent osteoporosis in later life [77]. 
Exercising during youth ensures higher peak bone mass is achieved [78, 79] as well as 
delaying the onset of age related decline in BMD [80, 81]. Bone strength is determined 
by its mass and density. Regular activity is linked with an increase in bone density [82]. 
Forces acting on bone from muscle contractions or other impact activities stimulate 
bone formation, while reduced loading with sedentary living or microgravity will 
decrease bone formation and can stimulate bone resorption. The physical activity level 
of an individual is therefore an important factor in bone health and a vital reason to 
encourage participation in sport. 
 
Bone’s adaption to exercise is mediated by cellular mechanotransduction [83]. 
Mechanosensors that are found throughout bone cells can change their structure 
following a strain on the bone. These changes stimulate the Wnt/-catenin signalling 
cascade [83] to be activated either by stimulation of a bone transcription factor 
(RUNX2) [84] or by cross talk with parathyroid hormone (PTH) and/or bone 
morphometric proteins (BMPs) [85-87]. Bone adapts to exercise through the muscle 
contractions [4, 88] associated with physical activity, impacts and ground reaction 
forces [76, 89].  
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There have been numerous studies conducted to understand the impacts of exercise 
and physical activity on bone health during ageing. Master athletes are those whom 
compete and train at an elite level, and usually have done so since a very young age. 
Several studies have looked at the master athletes as an example of ‘better ageing’. 
Wilks et al (2009) demonstrated the benefits of master athletes, firstly showing that 
sprint, middle and long-distance runners all have a greater tibial bone strength 
compared to controls [7]. This study consisted of 106 sprinters, 52 middle distance 
runners, 93 long distance runner, 49 race walkers and 75 age matched sedentary 
people. The tibia of master athletes was around 70mm2 greater in the athletes and the 
tibia had a trabecular BMD 50mg.mm3 greater than controls, in both male and female 
athletes. This was only found at the impacting tibia bone, results for bone strength at 
the radius did not show any obvious advantages in the athletes compared to controls. 
Wilks further investigated discipline specific advantages on bone health for these 
master athletes [8]. pQCT highlighted that diaphyseal bone mineral content, cortical 
area and polar moment of resistance were a much larger size in the sprinters. This 
increase then declined gradually over the distances, middle then long distance 
runners, race-walkers and controls having the lowest values. Sprinters had 
approximately 16% greater values than controls, similarly the periosteol circumference 
of the tibia was approximately 6% greater in sprinters than controls. The females 
tending to have a much greater difference to the controls than males. Again, very few 
differences between groups were found for the radius. These results show there is a 
bone expansion seen within the athletes allowing for greater muscle forces to be 
produced, in turn inducing a greater osteogenic effect on the bone, helping to enhance 
bone strength. From these studies it is clear to see that bone is able to adapt 
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throughout the life-span but this adaption is site specific and should be taken into 
account when prescribing exercise to older people. Whilst both of these master 
athlete studies demonstrate the advantages of training on bone, there was a large age 
range, of master athletes used for the study (33-94 years) making it difficult to know at 
what ages the differences become apparent.  
 
Numerous randomised controlled trials have been performed to investigate the impact 
of exercise on the ageing skeleton and to identify the most appropriate form of activity 
for the ageing population. These studies have shown both positive and negative 
outcomes. Woo et al., (2007) [90] compared Tai Chi and resistance training in a 
community dwelling ageing population. The study involved 90 men and women (total 
n=180) aged 65-74 years. After 12 months, training three times a week of either Tai Chi 
or resistance, the women showed a moderate attenuation in the loss of hip BMD, 
measured using DXA, (approx. 0.01% loss), with no changes in men, compared to a 
non-exercising group (2.25% loss). Whilst this outcome is positive for women, there 
are only minor benefits from 12 months of training. Duckham et al (2015) showed 
similar findings, [91]. Two falls prevention programmes were compared with regular 
care, the Otago Exercise programme (OEP) and the Falls exercise management (FEM) 
that involved both home and group exercises. Within this study there were a total of 
319 participants with an average age of ~72±5 yrs. The FEM involved 39 mins of group 
exercise a week and 30 min of home exercise per week, whilst the OEP group 
completed 58 mins a week of home exercise per week, with each intervention being 
carried out for 24 weeks. The aim of the falls programmes was to increase bone and 
muscle strength and to reduce the likelihood of falls in the future. There was no 
difference in femoral neck BMD or bone mineral content (BMC) between any of the 
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groups, nor was there an increase in BMD or BMC at any of the skeletal sites 
measured, using DXA. It was suggested that the exercises within the programmes did 
not exert a strain great enough to stimulate the bone and prevent further resorption 
within ageing. Whilst both these studies had high compliance rates ~80%, it may be 
that using the DXA as an outcome measure cannot pick up small positive bone changes 
but a pQCT may show internal structure or geometry changes of the bone that cannot 
be picked up using DXA. More studies are needed using these methods alongside DXA 
to see if this is the case. 
 
Several other studies have investigated the effects of a variety of exercises on bone 
health, Rantalainen et al (2011), [92], showed bilateral hopping for 12 weeks to have 
no effect on changing levels of circulating bone markers CTx, CICP and bALP, markers 
of bone turnover. These particular circulating bone markers have a short half-life and 
so changes can be hard to detect. Beavers et al (2017), [93], compared two groups of 
males and females aged 69±3.5 years (n=123). 63 participants underwent 5 months of 
resistance training, 3 days per week, whilst the remaining 60 people underwent 5 
months of aerobic training, 3 times a week. The resistance training involved 8 body 
exercises, each was done in 3 sets of 10 reps at 70% of the participant’s 1 repetition 
maximum. The aerobic training involved walking for 30 mins at 65-70% of maximum 
heart rate. Using DXA, BMD was measured at baseline and 5 months after the 
intervention. The results of this study showed the resistance training group to have no 
changes in their BMD, the aerobic group showed a significant decline in BMD (-7%). 
These findings further highlight the need for the exercises to exert high force strain on 
the bone and of a long enough duration to show positive effects on the bone health.  
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There are some studies that have showed positive effects on bone health through set 
exercise programmes. Elsisi et al (2015), [94], used a sample of elderly women aged 
~65±3.0 years, either assigned to circuit weight training or low pulse magnetic field for 
12 weeks, both interventions showed a significant increase in BMD and BMC of the 
lumbar spine, femoral neck and femoral trochanter (p<0.0001). Marques et al ,[95], 
and Tolomio et al [96], used combined exercise interventions of aerobic, strength and 
balance training. Marques et al (2011), [95], had a group of male and females (total 
n=60, aged~69±5.5), with the intervention conducted over 8 months, Tolomio et al 
(2008), [96], focused on osteoporotic women (n=49) with the intervention lasting 20 
weeks. Marques et al, showed an increase of 0.1g.cm2 at the femoral neck BMD, with 
no change in controls. Tolomio et al, improved all strength parameters of the lower 
limb, measured using phalangeal quantitative osteosonography.  Both interventions 
showing positive effects on the BMD and bone parameters measured. These findings 
can be compared to studies of bed rest or space flights whereby there is no impact or 
physical activity and just 6 months of space flight can result in a 10% loss of BMD [97-
99]. 
 
These studies highlight that there is inconclusive evidence to show that exercise has 
beneficial effects on the ageing skeleton.  The majority of resistance training studies, 
discussed in this section, seem to show beneficial effects to bone density during 
ageing. It seems that the interventions not involving resistance training must produce 
strains on the bone that are of a level high enough and longer duration to produce an 
osteogenic response. More studies are needed to specify the exact type of exercise 
and duration that will help to slow down the loss of bone strength during ageing, as 
well as the different effects of the exercise between clinically relevant sites. 
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These conclusions are also confirmed by a number of systematic reviews and meta 
analysis conducted to assess the effect of physical exercise on bone density. Bolam et 
al (2013), [100] conducted a systematic review assessing the effects of physical activity 
on bone health but focusing on the effects on meddle-age and older men. Their 
analysis included 8 randomised controlled trials, of which the interventions were; 
walking (n=2), resistance training (n=3), walking and resistance training (n=1) and 
resistance training + impact activity (n=1).Out of the 8 studies, 5 had a score below 
50% on the authors quality scale and the interventions varied in terms of frequency, 
intensity and duration. Six of the studies showed positive effects on BMD, while two 
showed no significant changes. The resistance training studies showed to be the most 
likely to produce a response in BMD, whereas walking alone had very little benefit. 
They also concluded that more high quality intervention studies are needed to 
establish the precise optimum exercise regime. Similarly in randomised controlled 
trials for post-menopausal women, another systematic review (n=17) by Yeh et al 
(2018) [101] has shown exercise to have a moderate effect size on bone mineral 
density on the lumbar spine in post-menopausal women (5 randomised controlled 
trials, 311 participants, SMD=0.38, 95% CI:0.08-0.68). Whilst a moderate effect size 
was reported only one of the studies showed a significant change in BMD (p=0.011). 
Again, demonstrating the need for consistency in randomised controllled trials. A 
systematic search was also performed, initially, for this section, results and search 
criteria of which can be found in appendix 1. 
 
Monitoring levels of habitual physical activity can also be a limiting factor within these 
studies, as habitual levels can vary greatly within a population, one way could be to 
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use accelerometry measurements [102]. However, it should be noted that some 
accelerometers may only register vertical impacts and not horizontal components of 
acceleration [103].  Further research is needed to test whether overall (horizontal and 
vertical) accelerations are associated with bone adaptations observed in different 
types of physical activity. 
2.1.4 Muscle 
Skeletal muscle is made up of fibres that usually run the total length of the muscle or, 
for pennate muscle, they run diagonally from superficial to deep aponeuroses. Within 
each fibre there are myofibrils and within myofibrils there are units known as 
sarcomeres. A contraction of a muscle occurs at the sarcomere level. Filaments of the 
sarcomere (actin) slide across thicker filaments (myosin dimers). The more myofibrils 
that a fibre contains, the greater the maximal force [104]. Muscles are innervated by 
motor neurons; these neurons carry the signal to the muscle to instigate contractions. 
A motor unit describes a single motor neuron and the muscle fibres that are 
innervated by the branches of that neuron [105]. A whole muscle contraction occurs 
when the individual motor units are activated. An action potential passes along the 
motor neuron axon and its branches to reach the neuromuscular junction. At this 
junction, acetylcholine is released from vesicles at the axon terminal into the synapse 
cleft. The acetylcholine then binds to receptors on the cell surface of the motor end 
plate on the muscle fibre [105], stimulating an action potential to travel along the 
sarcolemma and through t-tubules. The end result causes a release of calcium from 
the sarcoplasmic reticulum into the muscle fibre sarcoplasm [104]. The calcium binds 
with troponin, causing a conformation change in tropomyosin, exposing the myosin 
binding site on actin, allowing the myosin head to bind with actin. Adeonosine 
triphosphate (ATP) is hydrolysed to liberate energy needed for the ‘power stroke’ as 
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the myosin head rotates to ‘pull’ actin towards the centre of the sarcomere to 
generate force, or tension. ATP binding with myosin allows myosin to detach from 
actin. This process continues for as long as calcium is available in the sarcoplasm, and 
in turn, calcium will continue to be released into the sarcoplasm for as long as action 
potentials continue to arrive at the neuromuscular junction (assuming no fatigue 
occurs). 
 
There are three main fibre types that are each associated with different types of 
exercise based on the motor units and their differing capacities. Type 1 fibres are 
found in low threshold motor units, they have a low velocity of shortening during 
contraction, are enriched with mitochondria and myoglobin and are fatigue resistant. 
These fibres benefit from endurance performance or other prolonged activity. Type 2a 
muscle fibres usually have a larger cross-sectional area than type 1, along with a faster 
velocity of contraction and intermediate levels of mitochondria. Type 2x fibres have 
the largest cross-sectional area, fastest velocity of shortening and lowest 
mitochondrial content but higher glycolytic activity. The type 2x fibres fatigue quickly 
but generate high power and are found in the highest threshold motor units. These 
fibres are associated and used more within power and sprint training [106].  
 
The maintenance of muscle mass is regulated by the balance of protein breakdown 
and protein synthesis. This protein synthesis is regulated by the physical activity that is 
undergone by the muscles as well as the type of food that is ingested. Leucine is an 
essential amino acid, found within the make-up of certain proteins. This amino acid 
has the ability to inhibit the enzymes, classed as proteasomes, that are responsible for 
the breakdown of protein. During ageing, muscle becomes less able to respond to 
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physical activity and protein ingestion, and may require a greater amount of protein 
per day to elicit an anabolic response [107-110].  
 
2.1.5 Ageing and Muscle 
Ageing has a great effect on skeletal muscle. At the age of 40 years old, lean muscle 
mass begins to decline. After the age of 50 years old, muscle mass declines approx 1-
2% per year, with a total decline of around 25% between 50 and 75 years old [111-
114]. 
 
The strength of muscle also declines and the rate of decline increases with advancing 
age [115]. Power can be determined as muscle force x velocity of contraction and 
declines of power are greater than those of maximal force because muscles also slow.  
The velocity at peak power has been shown to decline around 18% during middle age 
and then a further 20% between the ages of 80 and 89 years. Other studies have also 
shown muscle size and strength to decline 68% from young (25 years) to old (71 years) 
[116]. The loss of muscle mass with age can be partly attributed to an acceleration in 
the atrophy of fast twitch muscle fibres (type 2x), these fibres have a reduction in cross 
sectional area at an increased rate than the type 1 fibres. The proportion of type 1 to 
type 2 fibres, however, remains the same [117, 118]. It has been suggested that the 
action potential resulting in a release of calcium into the sarcomere, becomes 
impaired leaving a less tense muscle, deemed as muscle weakness [119, 120]. Specific 
tension of single fibres decreases with old age and results in a reduced muscle specific 
force, further contributing to weakness in old age along with low muscle mass [121]. 
As muscle mass declines, connective tissue and fat replace the area previously 
 29 
occupied by the muscle fibres. This further hinders the maximum contractile force of 
the muscle [105]. 
 
The loss of muscle fibres with age is associated with death of motor neurons. Studies 
on human cadavers have revealed that those aged around 75 years old have around 
30% fewer motor neurons innervating lower limb muscles [122-124], and within the 
vastus lateralis there have been shown to be as much as 40-50% fewer motor neurons 
[117]. These findings have recently been supported using electromyography 
measurements indicating a loss of 30-50% of motor units by the age of 70 years old 
[105, 116]. Once muscle fibres become denervated, they may not all atrophy and die 
off, some may be reinnervated by remaining nearby axons. As a result, the motor unit 
becomes larger, but throughout the muscle as a whole, the number of motor units 
reduces [116, 125, 126]. This reinnervation also results in fibre type grouping [126, 
127].  
 
There are other factors that play a role in the decline in muscle size and strength. 
Satellite cell numbers reduce with age. Satellite cells are usually responsible for the 
repair of muscles in response to injury and damage. A reduction of these with age 
results in a slower response of the muscle to injury and a delayed repair [128-130]. An 
in-balance between the rate of protein synthesis and the rate of protein breakdown is 
more likely to occur as, in the elderly, food intake and appetite tend to decline [131]. 
Additionally, levels of certain hormones, such as oestrogen, progesterone and cortisol, 
change with age which can also have an effect on the muscles. The decline in human 
growth hormone reduces the amount of growth and repair. Cortisol levels also rise and 
can increase skeletal muscle fibre atrophy, whilst testosterone and oestrogen 
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reduction has been associated with decreased muscle mass and protein synthesis [25, 
132, 133]. 
 
In 1989, Rosenburg proposed the definition of sarcopenia as the “progressive decline 
of muscle mass and strength”. Sarcopenia is normally associated with increased risk of 
falling and fracture, loss of independent living, hospital admission and increased 
mortality [134, 135]. An updated definition of sarcopenia characterises the syndrome 
as progressive loss of muscle mass and strength associated with an increased risk for 
physical disability, poor quality of life and death [136-138]. There are many ways in 
which sarcopenia may be defined including, but not limited to, muscle mass, muscle 
strength and physical performance (walking speed or grip strength) [137, 139]. Current 
estimates suggest approximately 200 million people worldwide will be affected by the 
year 2050 [140]. The prevalence of sarcopenia increases with age, amongst 60-70 year 
olds approximately 5-13% are affected by sarcopenia, when aged over 80 years old, 
the proportion affected ranges from 11-50%, with a greater amount of men effected 
compared to women [141-143].  
 
Ageing also triggers a pro inflammatory response characterised by higher levels of 
circulating tumour necrosis factor-alpha (TNFα) and C-reactive protein, which is linked 
with a gradual decline in physical activity, presenting as low grade chronic 
inflammation [144]. Studies have shown that sarcopenia is accompanied by increased 
levels of inflammation factors TNFα and Interleukin-6 (IL-6), these factors have a 
catabolic effect in the long-term, accelerating muscle and bone tissue declines [134, 
145, 146].  
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In one population study, a sample of sarcopenia patients had a morbidity rate of 17% 
in males and 19% in females [144]. The progression towards sarcopenia ultimately 
involves alterations in skeletal muscle protein turnover; when the rate of muscle 
breakdown exceeds the muscle protein synthesis [144]. Interventions targeting the 
inflammatory responses that are associated with sarcopenia have not been successful 
and do not seem to be able to manage the atrophy of muscle, nor has it been explored 
in full detail [144, 147].  
As sarcopenia is a multifactorial condition, no single factor intervention study has been 
shown to have great effects. A combination of intervention and life style changes are 
what is needed to help reduce the loss of muscle size and strength in later life. The 
main focus of these interventions should target nutritional strategies that ensure 
sufficient energy and protein intake, maintain physical activity and reduce low grade 
inflammation [144, 146]. A summary of the changes in muscle mass, motor units and 
fibres during ageing, as discussed in this section, are shown in figure 2.3. 
 
Figure 2.3; A comparison between young and old muscle, showing motor unit remodeling, 
reinnervation, reduction in muscle size and fibre type grouping. Adapted from [105]. 
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2.1.6 Exercise and Muscle 
Physical activity has positive effects on muscle mass in ageing, in particular reducing 
the prevalence of sarcopenia in older age. Interestingly, it has been shown, within 
samples of local communities that sarcopenia is associated with a higher mortality rate 
and the greatest predictor of this mortality rate is a low physical function. Landi et al 
(2016), [148], investigated the elderly population within the area of Sirente in Italy. 
364 subjects were used for the study, all aged ~ 85 (median range 80-100) years. These 
community members were assessed over the course of 10 years, of those Sarcopenia 
was identified in 103 participants. Additionally, 253 deaths were recorded, 10 of which 
were sarcopenic, 162 were non sarcopenic. Of those deaths, subjects with a low 
physical performance level had a greater mortality rate. Similarly, Mijnarends et al 
(2016), [149], investigated a large community within the Reykavik area, with 2309 
participants aged 66-93 years. Over a five-year period, the incidence of sarcopenia had 
more than doubled within the sample, rising from 7% to 16%. Those reporting a higher 
level of physical activity had a significantly lower likelihood of becoming sarcopenic 
with older age. Studies such as these highlight the importance of improving physical 
function as a way to reduce the rate of sarcopenia and related mortality. 
 
As exercise impacts on bone, section 2.1.3, master athletes have also been used as an 
example ageing population to demonstrate the effects of exercise on muscle. There 
are clear differences between the muscular strength of master athletes and age 
matched controls [150, 151]. The benefit, however, is only achieved within power and 
strength trained master athletes, endurance trained athletes show no difference in 
muscle strength and size to that of age match controls [152-154]. The extent to which 
 33 
consistent training over a number of years effects muscle in ageing has been well 
reviewed by McKendry et al (2018), [150] in which the authors highlighted that, due to 
the wide variety of methods applied, it cannot be concluded if muscle mass and 
morphology is maintained better in trained master athletes. Although, most studies 
showed no differences between groups of old and young, sprint and endurance, in 
muscle fibre architecture [155, 156]. This highlights the need for consistent methods 
for measurements of muscle ageing within this specific population group, and also the 
need for specific training definitions within ageing populations. 
 
Numerous studies have been conducted to investigate the varying effects of the 
different types of exercise and physical activity has on muscle and sarcopenia during 
older age. It is well known that resistance training increases muscle protein synthesis, 
strength and power without the need for any specific dietary interventions [157]. 
Elderly populations have been shown to respond to resistance training interventions, 
as clearly identified by Laussen et al (2015), [158], in which community dwelling older 
people, aged 70-85 years, took part in a 6 month progressive resistance exercise 
program. The training was carried out three times a week progressing from two sets of 
10 repetitions at 80% of their maximum to 3 sets of 12 repetitions at 80% of their 
maximum. Significant improvements were identified in all measures of physical 
function, stair climb, chair rise and short physical performance battery testing (SPPB; a 
combination of three balance stances, 5x chair rises and a timed walk at their usual 
pace, denoting a total score that gives an indication of physical function [159]) . The 
SPPB score improved by 2 points, the chair rise became 9 seconds quicker and stair 
climb improved by 1 second (p<0.03). Some studies have shown different 
improvements between male and females undergoing the same exercise program. For 
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example, Hanson et al (2009), [160], used tests such as the stair climb test, rapid walk 
and timed up and go as assessments of physical function, aimed at mimicking activities 
of daily living (Total n=59 average age~69±7 years). Following a 12-week strength 
training program. Women (n=27) improved their walking timed test, by 0.5 seconds, 
but not the stair climb, whereas men (n=23) improved their stair climb test, by 0.3 
seconds, but not the walking time test. These studies clearly highlight the physical and 
muscular function improvements that can be made in old populations via exercise. 
When reporting changes in sarcopenia prevalence it should be noted that there are 
several ways in which sarcopenia can be diagnosed, making it difficult to confirm the 
effects of the interventions [161]. 
 
Resistance training has shown to be effective in the older person, using different forms 
of delivery. Both, low volume resistance training and high-volume resistance training 
can be effective, as was shown by Reid et al (2008), [162]. Subjects aged ~78±8 years 
old were divided into two groups, one performing high velocity resistance training 
(n=22)at a lower load, the other performing low velocity but at a higher training load 
(n=23). The intervention was carried out for 16 weeks, with training sessions 
completed twice a week. The result showed both groups improved their leg strength 
(13% for high velocity and 16% low velocity) and frailty assessment scores, as noted 
previously these assessment methods may come from an extensive range, (1.4 and 1.8 
point improvement, respectively), with no differences between the two types of 
resistance training. Another study, Nunes et al (2016), [163], has also shown that low 
volume exercise (3 sets per exercise) and high volume (6 sets per exercise) can both 
increase muscular strength of the leg extensors, by approximately 20kg, over a 16 
week period, with participants aged approximately ~61±(54-68 median range) years.  
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Aerobic training has been shown to have some effects on reducing inflammation as 
well as over time reducing body fat percentage [164-166]. Nordic walking is designed 
to work all muscle groups, walking using poles which involve the upper body muscles 
as well as the lower limbs. A sample of osteoporotic or osteopenic women aged 
68.7±4.43 years were randomly assigned to a control group or an activity group [167]. 
The activity group performed Nordic walking for 60 mins 3 times a week for 12 weeks, 
the control group continued with no additional intervention.  During the 12 weeks, the 
activity group showed significant improvements in their skeletal muscle mass index 
and the strength of the knee extensors and flexors. The peak torque of the knee 
extensor improved in the exercise group from 97Nm to 108Nm, and the flexor from 
42Nm to 51Nm, over the 12-week period. There were no changes within the control 
group. However, the walking did not improve hand grip strength. Indicating greater 
forces may be required at the forearms to stimulate an overall improvement in muscle 
strength. Another study has shown that aerobic training can improve muscular 
function. This study has shown that the muscular function is improved by remodelling 
the contractile properties of muscle [168]. Using an elderly population of women aged 
71±2 yrs, 12 weeks of cycle ergometer training, carried out 3-4 times per week for 20-
45 mins showed an increase in size of type 1 fibres (16%) and an elevation (21%) in 
peak power of type 1 fibres. Clearly, aerobic training does have its place in additionally 
increasing muscle mass, power and strength amongst older populations. However, 
there is speculation that long term aerobic endurance training [169, 170] is more 
detrimental to both bone and muscle health in older age than resistance and power 
training [8, 164, 165].  
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Various studies have shown that the combination of both resistance and aerobic 
training provides the best means to enhance the aging musculoskeletal system [164-
166]. Results of a large longitudinal study were reported by the LIFE study group [171] 
in 2017. This involved 1,635 sedentary men and women aged ~78±5.4 years being 
enrolled in a randomised controlled trial, and then being followed up over the course 
of 2.6 years. General day to day physical activity was monitored using accelerometry 
data and self-reporting. The participants all had functional limitations, and they were 
randomised into a structured moderate intensity physical activity programme 
combining walking, resistance and flexibility, or a general health education 
programme. At baseline and 6,12 and 24 months the 400m gait speed and short 
physical performance battery test (SPPB) were performed as outcome measurements. 
Overtime, the time for gait speed and SPPB score improved significantly (p<0.001), 
which were associated with increases in physical activity by an increasing number of 
accelerometry counts. These improvements in physical activity also reduced the onset 
of disability within the sample. Such a study highlights not only that combined 
interventions can instigate physical improvements but also that a sedentary 
population of older age is still able to respond significantly to such an intervention.  
 
These studies have all shown that exercise is able to benefit the older population and 
improve muscular health and reduce the likelihood of onset of sarcopenia. Whilst 
there is a very large set of studies that all highlight the benefits of exercise there is still, 
yet to be defined, the most beneficial type and duration of exercise to reduce the 
prevalence of low muscle mass and onset of sarcopenia in old age. Most studies, as 
identified in this section, have used general ageing samples whom may already be 
active and/or healthy, and importantly, there are very few long-duration training 
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programmes reported in the literature. Similar conclusions have been drawn from 
systematic reviews, one particular review by Vlietstra et al (2018) [172] revealed that 
knee extension strength (p<0.01), timed up and go (p<0.0001), appendicular muscle 
mass (p=0.04) and leg muscle mass (p=0.04) all showed significant improvements in 
response to the exercise interventions, within older adults with sarcopenia. This 
review evaluated 32 full texts, but only 6 randomised controlled trials were found 
within the 32 full texts. This further demonstrates the positive effects of exercise on 
muscle mass and strength as well as highlighting the need for more randomised 
controlled trials with consistent methods. Lee et al (2018) [173], achieved similar 
results with their systematic review, which included seven randomised controlled trials 
and three cross sectional or longitudinal studies. Muscle mass, muscle strength and 
physical performance all improved significantly in the sarcopenic subjects. However, 
there was little consistency in the measurement of sarcopenia. A systematic search 
was also performed, initially, for this section, results and search criteria of which can 
be found in appendix 2. 
2.1.7 Muscle and Bone Interactions 
The mechanostat theory states that bone adapts to increased mechanical loading, 
(impact exercise), by increasing size and strength [4, 82, 174] with reduced mechanical 
deformation showing major declines in bone mass, size and strength [174]. There have 
been numerous heritability studies that estimate between 40-80% of the phenotypes 
of the skeleton can be attributed to genetics, similar proportions have also been 
reported for muscle traits [175-178]. Given these high proportions of genetic 
influences that underlie both bone and muscle, it is highly likely that there is a shared 
genetic component between muscle and bone [175-178].  
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Individually, both bone and muscle are able to act as endocrine organs, secreting 
substances into the circulation which, in turn, may act on other organs. In the late 
1970’s it was first recognized that muscle can act as an endocrine organ particularly in 
response to injury [179]. Myostatin was the first myokine to be identified [180, 181] 
and is now known as an inhibitor of skeletal muscle cell growth. IL-6 is also a known 
‘myokine’, defined by Pedersen et al, as a cytokine released by the muscle cells, usually 
in response to inflammation and injury, leading to increased plasma levels of IL-6 
[179].  Pedersen and her group also showed that contracting muscles led to a 19-fold 
increase in plasma concentrations of IL-6 comparatively to resting muscles [182]. There 
are numerous other myokines that have since been identified, IL-5; which was studied 
as having a role in cross talk between adipose and muscle tissue [183] and IL-7 has be 
shown to have possible effects on satellite cells during differentiation of myogenic cells 
[183]. Some studies have shown Irisin to convert white fat into brown fat [184], IL-15 
has been shown to be involved in reduction of adiposity and studies using mice over 
expressing the gene for IL-15 are associated with having a higher bone mineral density 
[185]. 
 
In 2003, Winkler et al provided evidence that osteocytes function as more than just a 
specified bone cell, it can also act as an endocrine organ, regulating bone density by 
secretion of circulating factors [9]. Another factor, osteocalcin, is released by bone and 
can circulate in the blood where it can interact with substances from the liver and 
adipose tissue, to enhance energy metabolism. The way in which osteocalcin interacts 
with the substances released from the liver and adipose tissue may pre-dispose people 
to obesity, diabetes and osteoporosis [10]. Some other factors released by bone cells 
are osteoprotegerin (OPG), expressed by osteocytes and osteoblasts. OPG can cause a 
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reduction in the number of osteoclasts produced by binding receptor activator of 
nuclear factor kappa-B ligand (RANKL) [11]. Dickkopf-1 (DKK1) [14] and sclerostin, are, 
primarily released by osteocytes [15], and negatively regulate bone formation. DKK1 
and sclerostin have both emerged as therapeutic targets to tackle osteoporosis [186]. 
Fibroblast growth factor 23 (FGF23) is produced by a wide variety of cell types, 
including osteoblasts and osteocytes. Once FGF23 is released into the circulation it is 
able to act on the kidney to increase excretion of phosphate and reduce production of 
1-25 OH Vitamin D [187]. Osteopontin (OPN) is an extracellular matrix protein released 
by osteoblasts, osteocytes and osteoclasts and facilitates bone resorption [16].  
 
Together, the paracrine and endocrine properties of bone and muscle have led to the 
proposal of ‘bone-muscle cross talk’. The interaction between muscle and bone can be 
highlighted during exercise as muscles increase their function to power movements. 
Uptake of glucose and fatty acids rises significantly to provide energy needed to 
maintain muscle contractions [13, 188]. Osteocalcin (Ocn) is a factor that is now readily 
researched and a good example of how bone and muscle may interact [13, 189]. 
Genetically altered mice with their gene encoding osteocalcin silenced, have been 
shown to run for around 30% less time than wildtype mice [13]. The same low exercise 
capacity was also found in 3-month-old mice lacking the osteocalcin receptor (Gprc6a) 
[190]. Ocn(-/-) mice knockouts and Osteoclacin mice knockouts in osteoblasts only, 
both showed a similar decline in exercise capacity indicating the absence of a bone to 
muscle signalling event, highlighting the importance of the bone-muscle cross-talk. Il-6 
also rises during exercises and enhances the ability to carry out the exercise and can 
interact with muscle and bone (as well as many other tissue types) causing different 
substances and molecules to be released to enhance exercise capacity (see Figure 2.4). 
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In summary, osteocalcin increased the uptake and breakdown of glucose and fatty 
acids in myofibres. Then, in turn, the rise in IL-6 secretion from muscle during the 
exercises triggered by osteocalcin allows glucose to be mobilised from the liver and 
fats to be broken down into fatty acids. Finally, IL-6 through regulation of bone 
resorption increases the amount of bioactive osteocalcin produced [13]. This is 
summarised in the figure below: adapted from [13]. 
 Figure 2.4: An illustration of how Osteocalcin remodeling in myofibres can be accountable for most of 
the IL-6 released during exercise. An example of bone and muscle cross talk. 
Uncarb Ocn: Uncarboxylated osteocalcin, FA: Fatty acid, GPRC6A: Osteocalcin receptor, IL-6: Interleukin 
6, ATP: Adenosine triphosphate. Red arrow indicates an increase in production, black arrow indicates 
direction Adapted from [13] 
 
There has been further evidence to the interaction between muscle and bone through 
injury. Healing of fractures are much delayed if there is muscle damage alongside the 
fracture, [191-194]. With open fractures in mice with paralyzed muscles, healing is 
delayed, whereas if the fracture is covered with a functioning muscle, healing time is 
significantly reduced, indicating that the muscle is able to secrete factors to the 
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surrounding bone, decreasing healing time [195]. This has not only been shown in mice 
but in a clinical setting in humans with open fractures of the tibia [196]. 
 
2.1.8 Osteoporosis and Sarcopenia 
As discussed in earlier sections, both sarcopenia and osteoporosis exist in similar 
population groups, those being elderly, sedentary and in particular for osteoporosis 
post-menopausal women. It is now well known that sarcopenia and osteoporosis 
frequently co-exist within older populations, the common links between the two 
comorbidities are shown in figure 2.5. In studies using older men, it has been shown 
that the measures of appendicular lean mass, 15-20% of the variability is explained by 
BMD [3, 197]. Similarly, with postmenopausal women, several studies have shown a 
strong positive correlation between whole body lean mass and whole-body BMD [198-
201]. Using the mechanostat theory it would be expected that changes in bone mass 
are mediated by changes to the muscle strain (mechanostat). Therefore, numerous 
exercise intervention studies into muscle or bone have been conducted, as reported in 
sections 2.1.3 and 2.1.6, in an attempt to identify the best type and necessary duration 
of exercise to improve muscle and bone health during ageing. There is still yet to be 
defined a clear exercise programme for the ageing population. 
While the role of direct forces applied through muscle tendons onto bone is 
reasonably well established as a mechanism of bone growth or decline, the role of 
circulating factors mediating muscle and bone development, or decline remains 
unclear. The circulating bone factors previously mentioned, however, are still yet to be 
fully established and some have speculative roles amongst bone-muscle cross talk, 
especially within ageing. 
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Figure 2.5; Adapted from [127]; How sarcopenia and osteoporosis may come to co-exist in older age.  
 
The research completed as part of this PhD study will provide novel insights into how 
exercise and circulating bone regulatory factors may influence both bone and muscle 
health within older age. If specific regulatory factors with osteogenic and/or myogenic 
potential can be identified, it may lead to new therapeutic targets to help combat both 
osteoporosis and sarcopenia in older age. If we are able to identify the most beneficial 
type of exercise for ageing muscle and bone this will help to inform the general 
population on how to slow down the decline of muscle mass and bone strength in 
older age. 
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2.2 Aims and Objectives 
 
The overarching aim of the PhD project was to investigate how exercise and circulating 
bone regulatory factors influence both bone and muscle health in older age. This was 
achieved through four objectives: 
1. Investigate the relationship between BMD and lean mass in athletic older people, 
taking into account accelerometry data, the training age and type of athlete (sprint 
or endurance). 
2. Identify the circulating bone remodelling factors associated with BMD in healthy 
young and older adults.  
3. Identify the circulating bone remodelling factors associated with whole body lean 
mass in healthy young and older adults.  
4. Using the selected circulating factors identified in objective 2 and 3, investigate the 
responses of cultured human immortalised myoblasts after exposure to these 
factors. 
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3.1 Chapter 3: Hip and spine bone mineral density are increased in master sprinters 
compared to endurance runners and controls. 
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3.1.2 Abstract 
Purpose: The relationship was examined between prolonged participation in regular 
sprint or endurance running and skeletal health at key clinical sites in older age. 
Methods: Participants included 38 master sprint runners (28 males, 10 females, mean 
age 71±7y), 149 master endurance runners (111 males, 38 females, mean age 70±6y) 
and 59 non-athletic controls (29 males, 30 females, mean age 74±5y). Dual X-ray 
absorptiometry was used to assess hip and spine bone mineral density (BMD), body 
composition (lean and fat mass), whilst jump power was assessed with jumping 
mechanography.  In athletes, vertical impacts were recorded over 7 days from a waist-
worn accelerometer, and details of starting age, age-graded performance and training 
hours were recorded.   
Results: In ANOVA models adjusted for sex, age, height, body composition and jump 
power, sprinter hip BMD was 10% and 14% greater than that in endurance runners and 
controls respectively. Sprinter spine BMD was also greater than that in both endurance 
runners and controls (11% and 6%, respectively).  There were no differences in hip or 
spine BMD between endurance runners and controls.  Stepwise regression showed 
only discipline (sprint/endurance), sex and age as predictors of athlete spine BMD, 
whilst these variables and starting age were predictive of hip BMD. 
Conclusions: Regular running is associated with greater BMD at the fracture-prone hip 
and spine sites in master sprinters but not endurance runners.  These benefits cannot 
be explained by indicators of mechanical loading measured in this study including 
vertical impacts, body composition or muscular output. 
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3.1.3 Introduction 
To follow on from the findings in the literature review, the different effects of sprint 
and endurance training on bone mineral density were investigated. Clinically relevant 
sites, the hip and spine, were designated as the two bone outcome measures. To 
explain any differences between groups accelerometry data was collected along with 
muscle power and body composition, addressing the first objective for this PhD. 
 
Bone adapts to the mechanical loading it experiences during everyday physical activity 
(PA) and exercise, with higher impacts associated with intense PA being advantageous 
for bone strength [4, 82, 174].  Older people are usually less active than young and 
what activities they do engage with tend to be low impact and therefore of little 
benefit to bone [76].  This age-related decline in physical activity likely contributes to 
declining bone strength. Indeed, positive associations have been reported between PA 
levels and bone strength in older adults [76, 202], suggesting that exercise is an 
effective way to improve and maintain bone mineral density (BMD) and bone strength 
in older individuals.  Interventions designed to improve bone strength through exercise 
training have shown some significant improvements in adults, there is still a proportion 
of which have failed to show clinically significant effects [203]. A possible explanation 
for this is that bone adaptation in adults is slow and effects of exercise may take 
several years to fully manifest [6]. There is also uncertainty over the types of activities 
that are potentially osteogenic.  
 
Master athletes offer a model to examine associations between long term exercise 
training and bone strength, and have the added advantage that comparison can be 
made between different disciplines to determine which activities are more osteogenic. 
In young adults, the benefits of regular exercise have been suggested to depend upon 
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the type of activity, being greater in high impact activities such as sprinting whereas 
little benefit is evident in lower impact activities such as walking, cycling or swimming 
[204-206]. This may also be the case for older adults. For example, master cyclists have 
a higher incidence (80%) of osteopenia and lower hip and spine BMD than non-athletic 
controls (50%) [169].  In contrast, male and female sprinters had 15% and 18% greater 
trabecular BMD in the distal tibia than non-athletes [207], whereas benefits in male 
and female endurance runners were 7% and 9%, respectively. It remains unclear 
whether the benefits of sprint and endurance running are also observed in older age 
for the hip or lumbar spine, fractures of which represent a major disease burden.  In a 
small study of master athletes (n=26), total body, arm, trunk pelvis, legs, thoracic and 
lumbar spine regional BMD were greater in sprint athletes than controls with no 
advantages evident in endurance runners [208]. Previous studies have omitted 
comparisons with controls, considered younger athletes, been limited by small sample 
size or not investigated these regions [170, 207, 208].   
 
To the extent that observed associations between discipline and BMD reflect a 
response to exercise, different benefits of distinct running events on BMD are likely to 
be related to differences in skeletal loading by muscle and reaction forces between 
those activities. For example, the larger reaction [209, 210] and muscle forces in 
sprinting could explain the greater benefits to bone in sprint compared to endurance 
running. Direct assessment of vertical impacts and indirect indicators of muscular 
loading (lean mass and muscle power) in sprint and endurance runners would provide 
relevant information to test this hypothesis. 
 
 48 
It was hypothesised that both athletic groups have greater bone strength than 
controls, with the largest advantages in sprinters.  In addition, to the extent that any 
observed differences were a consequence of exercise participation, it was expected 
that the larger bone advantages in sprint than in endurance athletes are attributable 
to differences in physical activity (accelerometry data) and muscle mass and function.  
To investigate this, we compared hip and spine BMD between master sprinters, master 
endurance runners and non-athletic controls. We also examined differences in the 
number of vertical impacts and indicators of mechanical loading such as body 
composition and muscle power, and through ANCOVA and multiple linear regression 
models examined to what extent these could explain group differences.  
 
3.1.4 Materials and Methods 
3.1.4.1 Study Design 
Master athletes (MA) were recruited at nationwide athletics competitions as part of a 
multiple cohort study named “VIBE” and included male and female athletes aged ≥60 
years currently competing in sprint, middle or long distance running and in the 12 
months preceding recruitment had competed at regional level or higher. Regional 
ethics approval (14/NW0275) was obtained prior to the study and written informed 
consent was obtained from all participants.  
 
MAs were classified as sprinters (28 male and 10 female,) if competing in events less 
than 800m in distance, or endurance athletes (111 male and 38 female) if competing in 
events greater than or equal to 800m in distance. Each athlete completed a 
questionnaire to determine demographics, lifestyle, their past physical activity 
behaviours and physical activity at the time of wearing the accelerometer. The 
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questionnaire data allowed the athletes to be grouped according to years trained 
consecutively: 1) those training all of their life through childhood; 2) those training 
since 18 years old, 3) those training since 30 years old, and 4) those training since 50 
years old. Mean age-graded performance (AGP) was determined by taking the 
athlete’s highest ranked performance within the last two years, and expressing it as a 
percentage of the world record for that age and distance. AGP ranged from 77-92% 
across the cohort, indicating a high level of performance relative to respective age 
group records.  For example, a marathon of 3 hours and 30 minutes at the age of 70 
years gives an age-graded performance of 80%. 
 
The MAs were drawn as a sub-sample from a larger study that included 286 MAs with 
accelerometry measurements and of those, 189 participants also additionally 
completed DXA assessments at the Manchester research centre. These 189 
participants with both accelerometry and DXA data were included in the present 
study. The DXA images from two participants were excluded due to movement 
artefacts, so data are presented from 187 individuals with valid DXA and 
accelerometry data.   
 
Control participants were individuals recruited as part of the EU “MYOAGE” study 
[211] using advertisements in newspapers and University of the Third Age with the aim 
to recruit socially active individuals. Volunteers were excluded if: dependent living, 
unable to walk a distance of 250m, presence of morbidity (such as neurologic 
disorders, metabolic diseases, rheumatic diseases, heart failure, severe chronic 
obstructive pulmonary disease and haemocoagulative syndromes), immobilisation for 
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one week during the last three months, orthopaedic surgery during the last two years 
and/or suffering from pain or functional limitations. 
 
3.1.4.2 DXA Scans 
Standing height was measured to the nearest millimetre and body mass was measured 
to the nearest 0.1 kg. Whole body, total hip and lumbar spine dual energy X-ray 
absorptiometry (DXA) scans were performed using a DXA scanner while the participant 
lay supine (Lunar Prodigy Advanced, GE Healthcare, encore version 10.50.086).  During 
the measurements, a light cotton t-shirt was worn by the participants to reduce 
measurement errors due to clothing absorption. Body composition (fat mass and lean 
mass) was measured from total body scans, whilst bone mineral density (BMD, g.cm-2) 
was measured from hip and spine scans. All measurements were recorded after 
manual adjustment of the regions of interest carried out offline. Repeat total body and 
hip DXA scans were performed in 8 MAs within one month of the original scan. Using 
these repeat scans the short-term error for our laboratory was 2.0% for hip BMD and 
0.9% for spine BMD.  
 
3.1.4.3 Muscle function  
A Leonardo Mechanography Ground Reaction Force Platform (Leonardo Software 
version 4.2: Novotiec Medical GmbH, Pforzheim, Germany) was used to assess lower 
limb muscle function during a vertical jump as described previously [212] and 
described below. From this, both absolute and relative power was assessed. Briefly, 
the participants performed a two-footed countermovement jump where each 
participant was asked to jump as high as they could. Jumps were performed with a 
trained assistant present and in reach of the participants in case of a fall or falter. Each 
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participant repeated the jump sequence three times, with approximately 30 seconds 
rest between jumps. The jump with the maximum power was used for statistical 
analysis.  
 
3.1.4.4 Accelerometry 
Accelerometry data was collected from the athletes only. Each athlete received a 
GCDC ×16–1c (Gulf Coast Data Concepts, Waveland, Mississippi) which was placed in a 
Velcro strap and worn around the waist with the accelerometer device placed over 
their right hip. Each athlete wore this monitor for 7 consecutive days, only removing it 
when showering, bathing, swimming and sleeping. The monitor was kept on for all 
other daily activities including athletic training. Time sheets were completed over the 
7-day period to identify the time the monitor was first worn, the time it was removed 
in the evening and to indicate any reason why that day was not of their usual routine. 
Accelerometers were configured with standardised settings prior to participant use 
with a sampling frequency of 50 Hz, a deadband setting of 0.1 g (the threshold which 
must be exceeded before a recording is made) and a timeout setting of 10 s (meaning 
that a single sample every 10 s is taken even if the recording is <0.1 g) [102]. Once the 
period of use was completed the participant returned the accelerometer to the centre, 
by post, where the raw accelerometry data was then uploaded to a secure shared 
drive and read into Stata 13 (StataCorp, College Station, TX). A standardized cleaning 
and processing procedure was used [102]. The Y-axis accelerations data were cleaned 
to remove movement artefacts and any periods of nil data collection, presumably due 
to the participant not wearing the accelerometer. Activity data were normalised based 
on seven valid days of 14 hours with ≥10 h recording time. Y-axis peaks were 
calculated based on accelerations higher than the previous and subsequent reading 
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and recorded within 14 pre-specified g bands. These were condensed to three impact 
bands; low (≥0.5 to <1.0 g), medium (≥1.0 to <1.5 g) and higher (≥1.5 g) impact. All g 
values represent g over and above 1 g from earth’s gravitational force [76].  
 
3.1.4.5 Statistical Analysis 
Statistical analysis was performed using SPSS for Windows (v21, IBM, USA). Data was 
firstly assessed for normality of distribution using P-P and Q-Q graphs, and the 
Kolmogorov-Smirnov test. Accelerometry data was not normally distributed, so this 
data was log transformed for further analysis. Non-normally distributed data are 
presented as median (25th/75th) quartiles and all other data are presented as mean ± 
standard deviation (SD).  
 
Univariate ANOVA analysis with Fisher’s Least Significant Difference post-hoc tests was 
used to identify differences between the three groups (sprinters, endurance runners 
and controls). Males and females were combined in the statistical analysis and 
differences were determined with adjustment for sex. There was no evidence of group 
* sex interaction, therefore data from both sexes were combined for analysis. 
Differences were considered significant at p<0.05. Lean mass [213] and muscle 
function [214] are highly correlated with bone strength, even when accounting for 
allometric scaling. Therefore, these and other co-variates were included to assess 
group differences in bone outcomes using a series of five different models, as shown in 
Table 3. Model 1: age, height, sex; Model 2: model 1 + fat mass; Model 3: model 1 + 
lean mass; Model 4: model 1 + lean mass + fat mass; Model 5: model 4 + absolute 
power.  
 53 
 
To further investigate factors associated with bone outcomes in the athletes, single 
factor linear regression was performed for each individual variable (age, height, AGP, 
training age, hours trained, fat mass, lean mass, body mass, absolute power, vertical 
impacts (low, medium and high), discipline and sex) in relation to hip and spine BMD, 
for the athlete groups combined. Next, a stepwise linear regression was conducted 
with the athlete groups combined, using the same variables, to determine predictors 
of hip and spine BMD within Master Athletes. Results of regression analyses are 
presented as standardised regression coefficients (ß) and 95% confidence interval 
unless otherwise stated. 
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3.1.5 Results 
3.1.5.1 Participant characterisation  
Participant characteristics are shown in Table 1.  Controls were older than both sprint 
and endurance runners. There was no difference between any groups in height. 
Endurance runners were lighter and had lower BMI than both sprinters and controls, 
and sprinters also had lower BMI than controls.  Controls had 32% and 40% higher 
body fat percentage than sprinters and endurance runners, respectively.  Sprinters had 
greater lean mass and 10-30% greater relative and absolute power values than both 
endurance runners and controls. Lean mass but not absolute or relative power was 
also greater in endurance runners than controls.  
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Table 1. Participant characteristics separated by group and sex.   
Values are mean ± standard deviation; P-values for post hoc comparisons between groups are shown after adjusting for sex. 
Variable Group Group pair-wise comparisons 
 1. Sprint 2. Endurance 3. Controls 1 vs 2 1 vs 3 2 vs 3 
Sex M F M F M F 
N 28 10 111 38 29 30 
Age (years) 70.9±6.4 71.5± 7.9 69.9±5.7 69.1±50 74.1±5.7 73.3±4.5 .181 .022 <.0005 
Height (cm) 174±6 162±6 173±6 162±7 172±9 160±5 .467 .104 .180 
Body mass (kg) 74.3±9.7 62.9±10.9 67.9±7.7 56.0±7.4 80.2±16.2 63.1±11.5 <.0005 .098 <.0005 
BMI (kg.m-2) 24.5±2.7 23.9±3.8 22.5±3.1 21.4±2.1 27.1±4.7 24.5±4.2 <.0005 .012 <.0005 
Lean mass (kg) 57.8±5.6 43.8±4.7 54.2±5.4 41.3±5.0 52.2±8.4 38.1±4.3 .001 <.0005 .007 
Fat (%) 17.3±5.7 25.0±10.3 15.6±5.7 22.5±7.2 29.9±8.7 34.2±9.0 .136 <.0005 <.0005 
Absolute Power (kW) 2.64±0.90 1.68±0.59 2.03±0.56 1.41±0.38 2.19±0.59 1.46±0.49 <.0005 .002 .179 
Relative Power  
(W.kg-1) 
35.3±10.4 27.3±11.0 30.1±8.1 25.2±6.0 27.5±5.2 23.0±4.9 .002 <.0005 .060 
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3.1.5.2 Characteristics related to athletic training 
Mean age-graded performance ranged was 82.2% across the cohort, indicating a high 
level of performance as shown in Table 2.  Age-graded performance was greater in 
sprinters than endurance runners.  There was no difference in the number of hours per 
week trained between sprinters and endurance. The number of impacts recorded in 
the low and medium bands were 2.2- and 3.0-fold higher, respectively, in endurance 
than sprint athletes, but the number of counts in band 3 (high impacts) did not differ 
between endurance and sprinters.  
 57 
Table 2. Athlete-specific characteristics, separated by athletic group and sex. 
Variable Group Group 
Difference 
P 
 1. Sprint 2. Endurance 
Sex M F M F 
 
Training Age 
(years) 
<18 
18-29 
30-49 
>50 
17 
2 
6 
3 
5 
1 
1 
3 
57 
12 
22 
18 
8 
3 
11 
15 
 
.140 
Current Training 
Hours per week 
 
0-1 
1-3 
4-7 
7+ 
0 
5 
18 
4 
0 
2 
4 
3 
2 
13 
59 
36 
0 
4 
19 
15 
0.111 
Age graded Performance (%) 82.3± 13.6 89.5± 11.4 76.5± 10.7 80.6± 10.2 .002 
Accelerometry low impact 
(0.5-1g) counts 
20876  
(12362-40738) 
14368  
(6623-33408) 
40882  
(28228-53412) 
37161  
(25787-55780) 
<.0005 
Accelerometry medium 
impact (1-1.5g) counts 
6434 
(2364-13692) 
3326 
(694-13081) 
33458 
(18847-49909) 
29868  
(21076-41859) 
<.0005 
Accelerometry (counts) high 
impact (>1.5g) counts 
131  
(9-693) 
37 
(4-293) 
193 
(20-1038) 
90 
(12-774) 
.291 
Values are mean ± standard deviation except accelerometry counts (median (IQR)), P-values for post hoc comparison between groups are shown 
after adjusting for sex. 
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3.1.5.3 Bone Mineral Density  
In minimally-adjusted Model 1, mean hip BMD in sprinters was ~10% greater than 
endurance runners and 9% greater than controls (Table 3).  Adjustment for fat mass in 
Models 2, 4 and 5 increased the differences between sprinters and controls, whilst 
adjustment for lean mass in Model 3 had little effect on group differences. There were no 
differences in hip BMD between endurance and controls for any model (all P > 0.15).  
 
Sprinters had greater spine BMD than endurance athletes in Model 1 and this remained the 
case after further adjustment in Models 2, 3, 4 and 5. There was no difference in spine BMD 
between sprinters and controls in minimally-adjusted model 1 or after lean mass 
adjustment in Model 3.  However, adjustment for fat mass in models 2, 4 and 5 showed 
values to be higher in sprinters than controls.  Conversely, greater spine BMD was found in 
controls than endurance runners in models 1 and 3, but these group differences were fully 
attenuated by adjustment for fat mass in models 2, 4 and 5. The adjusted means for each 
model of adjustment are presented in Figure 3.1 ((A; hip BMD) and (B; spine BMD)). 
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 Table 3. Bone outcomes separated by group and sex.   
Values are mean ± standard deviation, P-values for post hoc comparison between groups are shown after adjustment for sex.  Adjustments: M1; 
adjusted for sex, height and age, M2; M1 + fat mass, M3; M1 + lean mass, M4; M1+ fat mass + lean mass, M5; M4+ absolute power 
 
 
Variable Group  Group pair-wise comparison 
 1. Sprint 2. Endurance 3. Controls Model 1 vs 2 1 vs 3 2 vs 3 
 M F M F M F 
Hip BMD 
(g.cm-2) 
 
1.15±0.16 
 
0.97±0.11 
 
1.03±0.15 
 
0.88±0.11 
 
1.05±0.12 
 
0.88±0.13 
 
1 
2 
3 
4 
5 
<.0005 
<.0005 
<.0005 
<.0005 
0.001 
0.006 
0.001 
0.016 
0.002 
0.007 
0.184 
0.953 
0.159 
0.993 
0.980 
Spine 
BMD 
(g.cm-2) 
 
1.21±0.21 
 
1.02±0.18 
 
1.09±0.13 
 
0.89±0.03 1.15±0.17 0.95±0.15 
 
1 
2 
3 
4 
5 
<.0005 
<.0005 
0.002 
0.001 
0.004 
0.110 
0.001 
0.345 
0.009 
0.018 
0.010 
0.763 
0.005 
0.957 
0.923 
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Figure 3.1. Adjusted mean estimates separated by group in a series of ANOVA models (means ±SD) for A) hip and B) spine BMD adjustments: M1; adjusted for sex, 
height and age, M2; M1 + fat mass, M3; M1 + lean mass, M4; M1+ fat mass + lean mass, M5; M4+ absolute power. Asterisks indicate significant difference from 
endurance *- P < 0.05, * - P < 0.01, *** - P < 0.001. Crosses indicate significant difference from controls +- P < 0.05, ++ - P < 0.01, +++ - P < 0.
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3.1.5.4 Regression Analysis 
Results of linear regressions between individual athlete characteristics and bone outcomes, 
when adjusted for age, height, body mass and sex, are shown in Table 4. Discipline 
(sprinter), AGP and absolute jump power were positively associated with hip BMD, whilst 
later starting age, low and medium impact counts were negatively associated with hip BMD.  
Discipline (sprinter), training age, and fat mass were positively associated with spine BMD, 
whilst a later starting age, low and medium impacts were negatively associated with spine 
BMD.  
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Table 4: Results of linear regression between each individual athlete characteristic and bone outcomes in athletes only 
 
 
 
 
 
 
 
 
 
 
 
 
Data are adjusted for age, height and sex presented as standardised regression coefficient ().  1Test for linear trend between categories. 
Variable 
Hip BMD Spine BMD 
 95% CI P  95% CI P 
Discipline (Sprinter) 0.281 0.155 0.408 <0.001 0.268 0.145 0.390 <0.001 
AGP 0.131 -0.004 0.266 0.059 0.100 -0.029 0.229 0.130 
Training Age1 -0.231 -0.366 -0.096 0.001 -0.153 -0.284 -0.021 0.024 
Training Hours1 0.017 -0.118 0.151 0.809 0.017 -0.109 0.144 0.791 
Fat Mass 0.102 -0.032 0.235 0.137 0.230 0.104 0.356 <0.001 
Lean Mass 0.093 -0.168 0.354 0.485 0.216 -0.039 0.471 0.099 
Absolute Jump Power 0.150 -0.005 0.304 0.060 0.174 0.023 0.326 0.025 
Accelerometry 
Counts 
Low -0.177 -0.040 -0.314 0.012 -0.246 -0.117 -0.375 <0.001 
Medium -0.169 -0.032 -0.306 0.016 -0.296 -0.169 -0.422 <0.001 
High 0.109 -0.034 0.252 0.137 -0.056 0.080 -0.193 0.420 
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In stepwise multiple linear regressions, the variables identified as predictors of hip 
BMD were sex (greater values in males, standardised regression coefficient 0.393, 
95%CI 0.257 to 0.529, P < 0.001), discipline (greater values in sprinters, 0.246, 95%CI 
0.113 to 0.38, P < 0.001), age (-0.259, 95% CI, -0.128 to -0.39, P < 0.001) and starting 
age (-0.168, 95%CI -0.03 to -0.307, P = 0.012).  For spine BMD sex (male, 0.527, 95%CI 
0.4 to 0.654, P < 0.001), discipline (sprinter, 0.248, 95%CI 0.121 to 0.374, P < 0.001) 
and age (-0.13, 95%CI -0.003 to -0.257, P = 0.046) were identified as predictors.   
 
3.1.5.5 Sensitivity Analyses 
To examine the influence of regional lean mass on bone, analyses adjusted for 
appendicular or lower limb lean mass rather than whole body measures was 
performed.  In addition, analyses with lean and fat mass indices (lean or fat/height2 
respectively) and relative jump power was also carried out. Results of these alternative 
analyses (data not shown) were similar to those described above, therefore whole 
body measures and unadjusted body composition and peak power values were 
retained in analyses. 
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3.1.6 Discussion  
The main finding was that hip and spine BMD were greater in sprinters than endurance 
athletes and non-athletic controls. These differences remained after adjustments for 
body composition and muscle function. Endurance athletes had lower spine BMD than 
controls during initial analysis, but this difference disappeared after adjusting for body 
fat. These findings suggest that long-term endurance exercise has little benefit for hip 
and spine BMD. In contrast, long-term sprint training may help to preserve hip and 
spine BMD at levels considerably higher than those of non-athletic controls. This is the 
first study to compare hip and spine BMD of older master athletes from different 
training disciplines and controls in a large cohort. The hip and spine are important 
clinically because they are prone to fracture in old age. Previous studies were limited 
by the absence of a control group [170] or discipline-specific comparisons [206, 215], 
recruitment of middle-aged athletes [208], or focused on distal or less fracture-prone 
regions rather than hip and spine [207, 208, 215].   
 
The findings support previous observations of greater BMD in sprinters compared with 
endurance runners and controls [8, 170, 208] . A previous DXA study in younger master 
athletes (40-64y) reported similar bone outcomes for endurance athletes and controls, 
whilst distal tibia trabecular BMD as assessed by pQCT were greater for both sprint 
and endurance runners compared to controls [8] . The differences between hip and 
tibia adaptations to different forms of running could be explained by the biomechanics 
of running at different speeds. Knee and hip torques increase with increasing running 
speed, but the torque around the ankle tends to plateau at speeds above 5 metres per 
second [216].   
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In terms of factors underlying the discipline-specific advantages in hip BMD in sprinters 
which has been observed here and by others [170, 208, 217], sprinters had higher lean 
mass and jumping power than endurance runners and controls. Though absolute and 
relative jumping power was positively associated with both hip and spine BMD, this 
relationship was no longer observed once discipline was included in the regression, 
which other than sex and age was the only independent predictor of BMD at both 
sites. Taken together, these observations suggest that whereas differences in muscle 
function likely contribute to observed BMD differences between sprinters and 
endurance runners, this influence is only partially explained by muscle power as 
measured by jumping mechanography. This limitation may reflect that whilst a number 
of parameters relevant to bone loading, that were previously shown to be associated 
with bone outcomes, were measured [6, 76, 214, 218, 219], outcomes were not able 
to directly assess bone deformation, nor the loads placed upon bones by reaction and 
muscle forces.  A previous study employing detailed biomechanical assessment of 
running gait in sprint athletes identified kinetic variables as predictors of bone strength 
within a master sprinter population [220].  More detailed biomechanical analyses 
within different athletic populations may identify relevant components of the training 
stimulus.  Moreover, BMD is influenced by lifelong exposure to mechanical strain, as 
indicated by greater hip and spine BMD in retired youth athletes [221] at old age.  The 
muscle measures were only obtained at a single point in time relatively late in life. 
Given the known decrease in muscle bulk and function with age [211] particularly in 
athletes [222], this study may have significantly underestimated differences in muscle 
function between these two groups across the life-course.  
 
Mechanical loading on the skeleton is a reflection not only of muscle function, but also 
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participation in physical activity. High impact activities, even when rare are thought to 
be osteogenic based on positive associations found between high vertical impact 
activity and bone outcomes in non-athletic older individuals [202, 223]. The 
expectation was that sprinters would achieve greater numbers of high impacts than 
endurance athletes which was hypothesised to contribute towards their greater BMD. 
Whereas BMD was substantially higher in sprinters, the endurance athletes and 
sprinters had similar numbers of high impacts as measured using accelerometry. It 
should be noted that the accelerometers only registered vertical impacts and not 
horizontal components of acceleration.  Indeed, the power output and, most likely, the 
magnitude and rate of strains experienced by the bones during sprinting, are greater 
than those during endurance running predominately due to the horizontal rather than 
vertical impulses [103]. Further research is needed to test whether overall (horizontal 
and vertical) accelerations are associated with bone adaptations observed in sprint but 
not endurance runners.   
 
It is also conceivable that vertical impacts of lower magnitude, in the low and medium 
range, exert osteogenic activity. However, whereas we have previously observed that 
master athletes have considerably higher levels of low and medium vertical impact 
activity compared to controls [224], and in the present study endurance runners 
showed even greater numbers of low and medium impacts compared to sprinters, 
BMD in endurance runners was similar to that of controls and below that of sprinters. 
Indeed, low and medium impacts were inversely related to BMD. This inverse 
relationship may reflect the recent observation that low and medium impacts as 
recorded here are inversely related to BMI [225], of which the latter is positively 
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related to bone mass [226]. Within this study the observation was that spinal BMD was 
in fact lower than controls in minimally-adjusted models, which differences attenuated 
after adjustment for fat mass, is consistent with this explanation.  The absence of bone 
benefits in endurance runners could also be related to desensitisation of the bone by 
regular low-level habitual activity [227], and/or saturation of the response to high-
magnitude loading after a very small number of loading cycles [228, 229]. Therefore, 
the higher levels of low and medium-impact activity performed by endurance than 
sprint and control athletes may not contribute positively to bone strength. 
 An alternative explanation to mechanical influences explaining the difference 
between sprint and endurance athletes’ BMD could be a pre-existing self-selection bias 
in sport participation, possibly relating to aspects of body stature not captured by our 
methodology but otherwise influencing BMD.  This possibility has been proposed in a 
number of previous master athlete studies [206, 207, 230], but never explored.  
Studies of bone health in individuals beginning to take part in sprint and endurance 
events either in childhood or adulthood could examine whether such bias exists. 
 
3.1.6.1 Strength and Limitations 
The main strength of this study is the comparison of a large cohort of elite level master 
athletes competing at very high levels and with extensive training history of different 
disciplines, and controls.  This allowed the impact of muscle strength, body mass, body 
composition and vertical impacts on the BMD at the hip and spine, sites which are 
clinically important due to their susceptibility to bone fractures in old age, to be 
assessed. Previous studies have omitted comparisons with controls, considered 
younger athletes or did not investigate these fracture-prone regions [170, 207, 208]. 
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However, the cross-sectional nature of the study limits assessment of causal 
relationships between type of sport and BMD due to possible uncontrolled 
confounders.  For instance, there was little information about other factors potentially 
related to bone health, such as use of medications and nutrient intake including 
vitamin D, but it seems unlikely that these will have differed substantially between 
groups so as to explain the BMD differences we observed. In addition, a detailed 
training log was not taken, so some additional information about differences in 
exposure to higher impacts between sprinters and endurance runners may have been 
missed.  Another consideration is displacement of the accelerometer during training in 
extreme high impacts, affecting accuracy of readings. Additionally, master athletes 
may represent some selection bias in that they are genetically predisposed to these 
events, which is why they have achieved their success. These findings do not suggest 
that sprinting activity will prevent any ageing comorbidities. Further longitudinal 
studies would be needed to identify if sprinting produces greater increases in BMD 
compared to endurance running in those that have not been competing for the 
majority of their lives, before translating these findings to the general population.  
3.1.6.2 Conclusions 
Master sprint runners have greater BMD at the fracture-prone hip and spine sites, and 
greater lean mass and muscle power than healthy non-athletic controls, but no such 
advantages in BMD were evident in endurance runners. BMD advantages in sprinters 
were only partly explained by differences in lean mass and muscle function, whilst 
further adjustment for other indicators of skeletal loading including accelerometry 
measures within sprinters and endurance runners could not explain group differences. 
Further studies are required to identify to what extent discipline-specific advantages in 
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BMD relate to pre-existing differences in skeletal health, or to variance in skeletal 
loading not captured in this study. 
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4.1 Chapter 4: Circulating levels of Dickkopf-1, Osteoprotegerin and sclerostin are 
higher in old compared with young men and women and positively associated with 
whole-body bone mineral density in older adults 
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4.1.1 Abstract 
Purpose: To investigate the relationship between whole-body bone mineral density 
(WBMD) and levels of circulating factors with known roles in bone remodelling during 
‘healthy’ ageing. 
Methods: WBMD and fasting plasma concentrations of dickkopf-1, fibroblast growth 
factor-23, osteocalcin, osteoprotegerin, osteopontin and sclerostin were measured in 
272 older subjects (69 to 81 years; 52% female) and 171 younger subjects (18-30 
years; 53% female).  
Results:  WBMD was lower in old than young. Circulating osteocalcin was lower in old 
compared with young, while dickkopf-1, osteoprotegerin and sclerostin were higher in 
old compared with young.  These circulating factors were each positively associated 
with WBMD in the older adults and the relationships remained after adjustment for 
covariates (r-values ranging from 0.174 to 0.254, all p<0.01). In multivariate regression, 
the body mass index, circulating sclerostin and whole-body lean mass together 
accounted for 13.8% of the variation with WBMD in the older adults. In young adults, 
dickkopf-1 and body mass index together accounted for 7.7% of variation in WBMD. 
Conclusion: Circulating levels of dickkopf-1, osteocalcin, osteoprotegerin and 
sclerostin are positively associated with WBMD in community-dwelling older adults, 
despite the average WBMD being lower and circulating dickkopf-1, osteoprotegerin 
and sclerostin being higher in old than young. 
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4.1.2 Introduction 
The findings from Chapter 3 have shown that sprinters have an increased bone mineral 
density at the hip and spine, compared to endurance master athletes and controls. The 
differences could not be explained by the number of impacts, nor muscle function. 
Given this, the differences could possibly be accounted for by the interaction of 
circulating factors with bone. The following chapter investigates the correlation 
between circulating factors and bone mineral density in young and old populations, 
addressing the second objective for the PhD.   
 
 
Progressive loss of bone mineral density (BMD) in older age leads to osteoporosis as 
the balance of bone remodelling favours resorption of mineralised extracellular matrix 
over formation. This common change is characterized by ‘micro-architectural’ 
deterioration of bone tissue and increases the risk of fracture [2]. BMD can be affected 
by BMI, muscle size or the sex of the individual. Males generally have a higher BMD 
than females and a lower incidence of osteoporosis in older age [231]. The greater 
muscle size will induce a greater muscle force on the bone when contracting [4, 232-
234] and may stimulate osteoblasts at a greater rate, resulting in higher BMD [4, 234].  
 
Circulating factors influencing bone development have been implicated in the age-
related changes to BMD including interactions between 1,25 dihydroxyvitamin D3 
(25(OH) VitD), parathyroid hormone (PTH) and calcium [235-238]. In addition, 
regulatory factors released from osteoblasts during bone formation and osteoclasts 
during bone resorption can enter the circulation and their concentrations may be 
related to BMD in older age. 
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There are many circulating factors that could be involved in bone and muscle cross 
talk. Due to the bone-muscle interactions it may be feasible that the circulating factors 
could be associated with BMD and/or lean mass, but research in this area is lacking. 
Some of the candidate circulating factors possibly related to BMD include 
osteoprotegerin (OPG), which is expressed by osteocytes and osteoblasts and can 
reduce production of osteoclasts by binding receptor activator of nuclear factor kappa-
B ligand (RANKL) [11]. Osteocalcin (OC) is a major non-collagen protein of the bone 
matrix secreted by osteoblasts for bone formation, but released from the matrix 
during bone resorption [239]. Dickkopf-1 (DKK1) [14] and sclerostin, released primarily 
by osteocytes [15], negatively regulate bone formation and have emerged as 
therapeutic targets to tackle osteoporosis [186]. Fibroblast growth factor 23 (FGF23) is 
produced by a variety of cell types, including osteoblasts and osteocytes, and released 
into the circulation where it acts on the kidney to increase excretion of phosphate and 
reduce production of 1-25 OH Vitamin D [187]. Osteopontin (OPN) is an extracellular 
matrix protein released by osteoblasts, osteocytes and osteoclasts to facilitate bone 
resorption [16].  
 
It remains unclear how the combination of these circulating markers of bone turnover 
are related to BMD in older age. Therefore, the purpose of this study was to compare 
plasma concentrations of these markers between recreationally active, community 
dwelling older adults and a reference group of young adults, and to examine the 
association of these with whole-body bone mineral density (WBMD). It was 
hypothesised that older adults would have higher circulating levels of factors related 
to bone resorption compared with young, and higher circulating markers of bone 
resorption were expected to be associated with lower BMD in old age.  
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Therefore, the purpose of this part of the study (addressing Objective 2) was to 
measure plasma concentrations of selected factors with known regulatory roles in 
bone remodelling; to compare their concentrations between recreationally active, 
community dwelling older adults and a reference group of young adults, and to 
examine the association of these with whole-body bone mineral density (WBMD).  
 
4.1.3 Materials and Methods 
4.1.3.1 Study Design 
The cross-sectional European multi-centre MYOAGE cohort consists of relatively 
healthy older men and women (aged 69 to 81 years) and young adults (aged 18-30 
years) [211] as shown in table 5. The study was approved by ethics committees at each 
institute and written informed consent was obtained from all participants. Participants 
were recruited by advertisement in newspapers, the University of the Third Age and 
Association of Emerti. All measurements were performed according to standard 
operating procedures that had been unified at the study centres and data collection 
was ceased through December-March and July-August. Volunteers were excluded if: 
dependent living, unable to walk a distance of 250 m, presence of morbidity (such as 
neurologic disorders, metabolic diseases, rheumatic diseases, heart failure, severe 
chronic obstructive pulmonary disease and hemocoagulative syndromes), 
immobilization for one week during the last three months and orthopaedic surgery 
during the last two years or still causing pain or functional limitations. The inclusion 
and exclusion criteria were designed to ensure the selection of relatively healthy 
participants and to minimize the confounding effect of comorbidity on sarcopenia 
[211] and the use of bisphosphonates, calcium and vitamin D supplements was 
recorded. The present study included 443 participants (Leiden, The Netherlands 
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(young; n=35, old; n=75); Jyvaskyla, Finland (young; n=34, old; n=65); Tartu, Estonia 
(young; n=39, old; n=60), Paris, France (young; n=35, old; n=30) and Manchester, UK 
(young; n=28, old; n=42)) with complete BMD and bloods results. 
 
4.1.3.2 Dual-energy X-ray absorptiometry 
A whole body scan was performed using DXA while the participants lay supine, as 
previously reported [211] (The Netherlands: Hologic QDR 4500, version 12.4, Hologic 
Inc., Bedford, MA, USA; Finland: Lunar Prodigy, version en-Core 9.30; Estonia: Lunar 
Prodigy Advanced, version en-Core 10.51.006; France: Lunar Prodigy, version encore 
12.30; United Kingdom: Lunar Prodigy Advance, version enCore 10.50.086). A trained 
technician completed the daily equipment calibration and the DXA scans according to 
local and manufacturers’ quality control procedures. Participants wore a light cotton 
garment to reduce effects of clothing absorption on the scanning results. The whole-
body lean mass, fat mass and the WBMD were recorded after manual adjustment of 
the regions of interest carried out after the scan was complete. 
 
4.1.3.3 Blood sample analysis 
Blood samples were collected from a vein in the forearm into vacutainer EDTA tubes in 
the morning when participants were in a fasted state. Samples remained at room 
temperature for 15-30 min and were then centrifuged for 15 min at 2,000 *g at 4◦ C. 
The plasma was collected and stored at -80◦C until analysis. Plasma concentrations of 
the selected analytes were determined in the research laboratory in Manchester, UK, 
using multiplex immunoassays (Millipore, Billerica, MA, USA).  The manufacturer 
instructions were followed and the magnetic bead panels quantified DKK1, OPG, OC, 
OPN, sclerostin and FGF23 using a 96-well plate after an overnight incubation. The 
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sensitivity of each analyte was 1.4 (DKK1), 1.9 (OPG), 68.5 (OC), 37.7 (OPN), 31.1 
(sclerostin) and 9.2 (FGF23) pg/mL. Samples were processed using a Luminex 200 
Bioanalyser and protein concentrations were estimated using the xPONENT software 
(Luminex, v.3.1.871). 
 
4.1.3.4 Statistical analysis 
Participant descriptive characteristics (Table 5) were normally distributed and are 
presented as mean ± standard error of the mean (SEM). Comparisons between age 
and gender were assessed using multivariate ANOVA. Relationships between body 
stature, BMI, total body lean mass and supplement use (independent variables) with 
WBMD (dependent variable) were assessed using bivariate Pearson’s product moment 
correlation. Data for circulating factors were not normally distributed and are 
presented as median (25th/75th) centiles. The results were log-transformed and z-
scores calculated by expressing each log-transformed value as a standard deviation 
from the mean of the gender-matched young. Z-scores of WBMD, lean mass and BMI 
were also calculated for use in subsequent correlation and regression analysis. 
Spearman’s rho partial correlations were performed to assess relationships between 
the z-score WBMD with z-scores of circulating factors using two models. The first 
model included adjustment for country of testing to account for any systematic 
differences. The second accounted for the positive correlations we observed between 
WBMD and BMI in men and women (r-values ranging from 0.210 – 0.387) and WBMD 
and lean mass for men (r-values in men ranging from 0.268 – 0.357, and women 0.085 
– 0.099) as well as health status and use of bisphosphonates, calcium or vitamin D 
supplements. Thus, the second model included adjustments for: country of testing, z-
score of lean mass, z-score of BMI, self-reported health and supplement use. A 
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stepwise multiple linear regression using the self-reported health and supplement use 
as well as z-scores for BMI, lean mass and circulating factors was then used to evaluate 
which combination of the independent variables was associated with z-score WBMD 
(dependent variable) in older adults and in young adults. Data was analysed using SPSS 
for Windows (v.21; IBM, USA) and significance accepted as p<0.05. 
4.1.4 Results 
Based on z-scores relative to gender-matched young, 26% of the older participants had 
WBMD values between -1.5 to -2.49 below the mean for young and 10.6% were ≥ -2.5 
below the mean of young. There was a significant age-by-gender interaction for 
WBMD z-scores (p<0.0005). 
 
There were gender differences in all participant characteristics except for age (Table 
1). WBMD was significantly lower in old compared with young participants. Total lean 
mass was lower in old compared with young when expressed in absolute values (Kg) 
and also as percentage of total body mass due to old having higher fat mass than 
young. There was a significant age by gender interaction for total lean mass (p=0.025) 
and for WBMD z-scores (p<0.0005). 
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Table 5. Participant descriptive characteristics 
 Old Young p-value 
 Men 
(n=129) 
Women 
(n=143) 
Men  
(n=82) 
Women 
(n=89) 
Age  Gender 
Age (years) 74.6±0.3 74.0±0.3 23.6±0.3 23.2±0.3 <.0005 NS 
Height  
(m) 
1.74±0.01 1.61±0.01 1.81±0.01 1.67±0.01 <.0005 <.0005 
Body mass 
(kg) 
78.8±1.0 65.1±0.8 75.4±1.2 62.4±1.0 <.0005 .018 
BMI (kg/m2) 25.8±0.3 25.2±0.3 23.1±0.3 22.4±0.3 .017 <.0005 
Body fat (kg) 20.1±0.7 22.7±0.6 12.9±0.7 18.8±0.7 <.0005 <.0005 
Lean mass 
(kg) 
55.9±0.6 
 
40.2±0.5 
 
59.9±0.9 
 
41.4±0.6 
 
<.0005 <.0005 
Body fat (%) 25.5±0.6 
 
34.6±0.6 
 
16.6±0.7 
 
29.6±0.7 
 
<.0005 <.0005 
Lean mass 
(%) 
71.9±0.6 
 
63.0±0.6 
 
79.8±0.7 
 
67.2±0.7 
 
<.0005 <.0005 
WBMD 
(g/cm2) 
1.19±0.01 
 
1.04±0.01  1.25±0.01 
 
1.15±0.01 
 
<.0005 .001 
WBMD  
(z-score) 
-0.63± 
0.10 
-1.47± 
0.11 
0.00±0.11 0.00±0.11 <.0005 <.0005 
Values are mean ± SEM. WBMD: whole-body bone mineral density. NS; no significant 
difference. 
 
In older men and women, WBMD was significantly associated with body mass 
(r=0.407, p<0.0005; r=0.241, p=0.004, respectively), but not height (r=0.160, p=0.072; 
r=-0.087, p=0.308, respectively). In young men, WBMD was significantly associated 
with body mass and height (r=0.386, p<0.0005; r=0.218, p=0.050, respectively) and in 
young women WBMD was significantly associated with body mass, but not height 
(r=0.218, p=0.041; r=0.070, p=0.518, respectively). WBMD was significantly associated 
with BMI in older men (r=0.387, p<0.0005), older women (r=0.316, p<0.0005), younger 
men (r=0.329, p=0.003) and younger women (r=0.210; p=0.050). WBMD was also 
associated with lean mass in older men (r=0.268, p=0.002) and younger men (r=0.357, 
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p=0.001), but not in older women (r=-0.085, p=0.322) or younger women (r=0.099, 
p=0.361).  
 
Table 6 shows concentrations of the circulating factors. Compared with young, older 
participants had higher concentrations of DKK1, OPG and sclerostin. Concentrations of 
OC were significantly lower in old compared with young. OPN and FGF23 did not differ 
significantly between young and older participants although this was after removal of 
37% of FGF23 samples [similar proportions of young and old] that fell below the level 
of assay detection. Compared with men, women had higher circulating concentrations 
of OPG, but lower OPN and sclerostin. There were no significant differences between 
men and women for DKK1, FGF23 and OC. Age x gender interactions were found for 
OC, OPG and sclerostin (all p<0.05): the difference between young and old in OC, OPG 
and sclerostin was greater for men than it was for women. 
 
Table 7 shows the associations between circulating bone regulatory factors and 
WBMD. When using z-scores of all variables and including all participants, while 
adjusting for country, WBMD was positively associated with DKK1. This association 
remained significant after additionally adjusting for lean mass, BMI, self-reported 
health and supplement use. In older participants only, DKK1, OC, OPG and sclerostin 
were positively associated with WBMD after adjusting for country. This remained the 
case when additionally adjusting for lean mass, BMI, self-reported health and 
supplement use. In younger participants only, DKK1 was positively associated with 
WBMD after adjusting for country as well as when additionally adjusting for lean mass, 
BMI, self-reported health and supplement use. 
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Table 6. Circulating markers of bone remodelling in old and young, men and women. 
 Old Young p-value 
 Men Women Men Women Age Gender Age    x 
Gender 
DKK1 
(pg.mL-1) 
577.0 ± 
352-804 
575.3 ± 
346-864 
420.6± 
290-627 
494.3 ± 
284-703 
<.0005 .942 .843 
FGF23 
(pg.mL-1) 
113.5 ± 
72-274 
(n=75) 
103.0 ± 
64-211 
(n=87) 
122.9.7 
± 
87-195 
(n=54) 
141.7 ± 
94-225 
(n=60) 
.792 .316 .700 
OC  
(pg.mL-1) 
14160.5 
± 
9911-
18708 
16065.4 
± 
11073-
19933 
17581.1 
± 
13304-
21223 
16733.9 
± 
12013-
20715 
<.0005 .880 .036 
OPG  
(pg.mL-1) 
319.2 ± 
229-419 
306.9 ± 
257-392 
159.4 ± 
114-193 
208.5 ± 
160-260 
<.0005 <.0005 <.0005 
OPN  
(pg.mL-1) 
26590.1 
± 
17094-
38028 
21350.1 
± 
13971-
31255 
24822.5 
± 
16928-
35662 
20877.5 
± 
15937-
27777 
.700 .009 .184 
Sclerostin 
(pg.mL-1) 
5690.3 ± 
4348-
7556 
4147.6 ± 
3349-
5159 
3016.1 ± 
2079-
3932 
2366.0 ± 
1923-
3134 
<.0005 <.0005 .034 
Values are median ± 25th – 75th percentiles. For FGF23, the n is less than those given in 
Table 1 due to some samples having values that were below the level of detection. The 
n for all other analytes is the same as shown in Table 1. 
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Table 7. Associations between circulating bone regulatory factors and whole body 
bone mineral density.  
Correlation with z-score 
WBMD 
 all participants 
combined 
Old Young 
Adjustment models 1 2 1 2 1 2 
DKK1 r=.107 
p=.026 
r=.129 
p=.008 
r=.167 
p=.007 
r=.174 
p=.005 
r=.263 
p=.001 
r=.282 
p<.0005 
FGF-23 r=.067 
p=.274 
r=.051 
p=.406 
r=-.095 
p=.235 
r=-.079 
p=.330 
r=-.086 
p=.370 
r=-.130 
p=.182 
OC r=-.124 
p=.010 
r=-.083 
p=.088 
r=.150 
p=.015 
r=.187 
p=.003 
r=-.023 
p=.767 
r=-.008 
p=.916 
OPG r=-.096 
p=.047 
r=-.039 
p=.419 
r=.209 
p=.001 
r=.254 
p<.0005 
r=.081 
p=.297 
r=.055 
p=.484 
OPN r=-.005 
p=.918 
r=-.001 
p=.980 
r=.055 
p=.370 
r=.073 
p=.245 
r=-.120 
p=.124 
r=-.122 
p=.120 
Sclerostin r=-.091 
p=.059 
r=-.075 
p=.126 
r=.241 
p<.0005 
r=.240 
p<.0005 
r=.129 
p=.096 
r=.135 
p=.086 
Data are shown as spearman’s rho. The circulating bone regulatory factors were log-
transformed and their z-scores calculated. The p value indicates the level of 
significance after statistical analysis. Results were adjusted for 1) country; 2) country, 
z-score lean mass, z-score BMI, self-reported health and supplement use. Significant 
relationships are highlighted using bold text. 
 
Stepwise multiple linear regression was performed including z-score WBMD as the 
dependent variable and independent variables included: self-reported health, 
supplement use and z-scores of the variables BMI and lean mass, as well as the z-
scores derived from log-transformed data for DKK1, FGF23, OC, OPG, OPN and 
sclerostin. Results in the young showed DKK1 accounted for 5.1% of the variation in 
WBMD (adjusted r2=0.051, p=0.010), while DKK1 and BMI accounted for 7.7% of the 
variation in WBMD (adjusted r2=0.077, p=0.005). In the old, BMI alone accounted for 
8.9% of the variation in WBMD (adjusted r2=0.089, p<0.0005); BMI and sclerostin 
together accounted for 12.0% of the variation in WBMD (adjusted r2=0.120, p<0.0005), 
while BMI, sclerostin and whole body lean mass accounted for 13.8% of the variation 
in WBMD (adjusted r2=0.138, p<0.0005). 
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4.1.5 Discussion 
The results of this study showed that circulating factors DKK1, OPG and sclerostin were 
each higher in old compared with young, but positively associated with WBMD in older 
adults. Circulating OC was lower in old compared with young and positively associated 
with WBMD. In multivariate regression, BMI, circulating sclerostin and whole-body 
lean mass together accounted for 13.8% of the variation with WBMD in the older 
adults. In young, DKK1 and BMI together accounted for 7.7% of variation in WBMD.  
 
Low BMI [240] and low lean mass [3] in older age are known risk factors for osteopenia 
and osteoporosis, possibly due to lower loading on bones, particularly on weight-
bearing bones. Female gender and low BMI were independently associated with the 
lowest quartile (within the sample) of WBMD, while male gender, higher lean mass 
and BMI were independently associated with the highest quartile for WBMD. These 
findings were consistent with a previous report [161] and with other research linking 
age-related declines in BMD to reduced mechanical strains [241]. 
 
4.1.5.1 Circulating factors associated with whole-body BMD 
Four out of the six circulating factors differed in concentration between old and young 
(Table 2). Of those, DKK1, OC, OPG and sclerostin were identified from both partial 
correlation models as associated with WBMD in older participants (Table 3). 
Sclerostin and DKK1 are released primarily by osteocytes and inhibit bone formation 
by blocking the osteoblast Wnt/β-canenin signalling pathway [14, 242], with sclerostin 
and DKK1 also stimulating bone resorption through RANKL [243]. Down-regulation of 
sclerostin [186] and DKK1 [14, 186] is associated with markedly increased bone 
formation. For these reasons, an inverse association between circulating sclerostin and 
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DKK1 with WBMD would be expected, but is not entirely what was observed. In line 
with expectations, these results revealed, on average, a 1.8 fold higher circulating 
sclerostin and approximately 1.2-fold higher DKK1 in old compared with young, which 
is consistent with an inverse association between sclerostin and BMD in older age 
[244] and with results from a small sample of 36 patients showing an inverse 
association between DKK1 and lumbar and femur BMD [245]. However, contrary to 
expectations, the circulating levels of sclerostin and DKK1 were positively associated 
with WBMD in the older participants (Table 3). Similar positive associations between 
circulating sclerostin with BMD and bone micro-architecture in old age has been 
previously reported [246-249].  
 
Similar to the findings for sclerostin and DKK1, a paradoxical relationship existed for 
OPG and WBMD in older adults: circulating OPG was higher in old compared with 
young (Table 2), but circulating OPG was positively associated with WBMD (Table 3). 
OPG released by osteocytes and osteoblasts promotes bone formation. It has been 
shown to protect against generalised bone resorption by blocking TNFα in models of 
chronic inflammation [250] and is considered to be a decoy receptor for RANKL to 
reduce osteoclast-driven bone resorption [251]. There are conflicting reports about 
the direction of association between circulating OPG and BMD. A study of 
postmenopausal women of mean age 62 years [252], and a study of middle aged men 
[253] reported inverse relationships between BMD and OPG, while others reported no 
relationship [254, 255]. Conversely, and in line with the results of the present work, 
when adults in their eighth and ninth decades of life were included in the sample 
population the relationship between OPG and BMD was positive [256, 257]. These 
conflicting results cannot be explained by the differences between studies in skeletal 
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site examined. Conflicting results may be related to the differences in the age range of 
the study samples and possible gender differences. The results for OPG and sclerostin 
showed significant age x gender interactions indicating that the differences between 
young and older men were greater than those between young and older women 
(Table 2). It is already known that sex hormones can regulate bone turnover and may 
interact with these circulating factors [258]. 
 
It is not clear why circulating sclerostin, DKK1 and OPG were positively associated with 
WBMD in older age, despite the conflicting overall trend for higher circulating levels 
and lower WBMD in the old. One possibility is that the older, but healthy mature 
osteocytes generally release higher absolute levels of sclerostin, DKK1 and OPG into 
the circulation [259] [260]. For example, a positive correlation was found for 
circulating sclerostin with trabecular density, number and thickness in older men [246, 
259], suggesting the more advanced trabecular resorption in osteoporotic bone leaves 
fewer mature osteocytes and thus, lower sclerostin release than healthy older bone. 
However, analysis of bone biopsies showed similar sclerostin mRNA levels in young 
and old despite higher circulating sclerostin levels in the old [244] which indicates that 
the age-related differences in circulating sclerostin may not be due to increased 
osteocyte sclerostin gene expression, although this does not necessarily equal protein 
production [261].  
 
Lower circulating OC was found in old compared with young (Table 2) and, consistent 
with this, circulating OC levels were positively correlated with WBMD in the old (Table 
3). OC released by osteoblasts plays a role in bone formation, so the positive 
correlation with WBMD may be expected. However, others suggest that higher 
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circulating OC indicates greater rates of bone resorption because fragments or whole 
OC protein is released into the circulation during bone resorption [239]. A previous 
study of young and middle-aged women suggested that circulating levels peaked soon 
after menopause and dropped thereafter, although levels were higher in those with 
osteoporosis than those without [262]. Interestingly, these results also show a positive 
association between DKK1 and WBMD in the young adults from univariate and 
multivariate analyses. This association may be a reflection of the numbers of mature 
osteocytes or related to total bone mass, but more work is needed to confirm. One 
previous study of children and adolescents did not find any association between 
circulating DKK1 and BMD, but the young included in that study of youths were in 
stages of rapid developmental growth, which could present different results from the 
steady- state of young adults [263].  
 
4.1.5.2 Strengths and limitations 
The MYOAGE study included young and older participants relatively free from lifestyle-
related comorbidities for their age and the results are therefore indicative of age-
related effects. Nevertheless, the associations identified in this cross-sectional study 
cannot be interpreted as causal relationships despite the clear roles for the selected 
circulating markers in bone remodelling. The results for FGF23 showed no significant 
age- or gender-differences, nor correlations with WBMD, but a large proportion of the 
results were below the level of assay sensitivity, so firm conclusions cannot be drawn 
for this analyte. Circulating levels of markers have been measured, which may be 
influenced by release from non-bone cells, so it is not possible to determine the 
originating cell type. It is possible that altered renal function can affect the levels of 
the circulating factors, but markers of renal function was not included in the present 
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study due to limitation of plasma sample quantity. A phantom was not used to 
calibrate the DXA scanners across sites and results were not adjusted to derive 
“standardised” DXA values, as others have done for hip and femur sites [264]. Instead, 
all study centres followed the local quality control procedures, including use of 
phantoms and daily calibration and the results were adjusted for country of testing to 
account for possible systematic differences. 
 
Future studies should determine the reasons for the positive relationship between 
circulating sclerostin, DKK1 and OPG with BMD in older adults, despite the old having 
on average higher circulating levels of these factors and lower WBMD.  
 
4.1.5.3 Conclusion 
Sclerostin, DKK1, OPG and OC were each positively associated with WBMD in older 
adults, despite the average WBMD being lower and circulating DKK1, OPG and 
sclerostin being higher in old than young. Multiple linear regression identified BMI, 
circulating sclerostin and whole-body lean mass as explaining approximately 14% of all 
variation on WBMD amongst older adults. 
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5.1 Chapter 5: Circulating markers associated with whole body lean mass in older 
men and women. 
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5.1.1 Abstract 
Purpose: To investigate the relationship between whole-body lean mass (WB Lean 
mass) and levels of circulating factors with known roles in bone remodelling during 
‘healthy’ ageing. 
Methods: WB Lean mass and fasting plasma concentrations of dickkopf-1 (DKK1), 
osteocalcin (OC), osteoprotegerin (OPG), osteopontin (OPN), sclerostin and tumour 
necrosis factor-alpha (TNF) were measured in 272 older subjects (69 to 81 years; 52% 
female) and 171 younger subjects (18-30 years; 53% female). Spearman’s rho partial 
correlations were performed to assess associations between the z-score WB Lean mass 
with z-scores of circulating factors. Multivariate regression was used to examine the 
relationships between lean mass and the circulating factors. 
Results:  WB Lean mass was 5% lower in old than young. Circulating osteocalcin was 
lower in old compared with young, while dickkopf-1, osteoprotegerin, sclerostin and 
TNF were higher in old compared with young.  These circulating factors were each 
significantly (p<0.03) negatively associated with WB Lean mass in the older adults (OC; 
r=-0.175, DKK1; r=-0.312, OPG; r=-0.170, Sclerostin; r=-0.235) apart from TNF that 
was positively associated (r=0.140) with WB Lean mass in older adults. In multivariate 
regression, height and OPG accounted for 45% of the WB Lean mass in the older 
adults. In young the same combination of OPG and height accounted for 18% of 
variation in WBMD.  
Conclusion: These results identify OPG as a circulating factor significantly associated 
with whole body lean mass in young and older adults.  
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5.1.2 Introduction 
Chapter 4 has shown that circulating factors Osteoprotegrin (OPG), Sclerostin, 
Dickkopf-1 (DKK1) and Osteocalcin (OC) are significantly associated with whole body 
bone mineral density in older adults. Fourteen percent of the variation in whole body 
bone mineral density can be explained by BMI, sclerostin and whole body lean mass. 
Muscle and bone interactions have been highlighted in section 2.1.7. It is possible that 
the same circulating factors associated with whole body bone mineral density are also 
associated with whole body lean mass. This chapter, addresses objective 3, and 
investigates the associations between circulating factors, as measured in Chapter 4, 
and whole body lean mass in the old and young population.  
 
 
Skeletal muscle mass decreases progressively with advancing older age towards a 
condition known as sarcopenia characterized by low appendicular muscle mass, 
associated weakness and reduced physical function [115, 135, 265]. At the same life 
stage, the skeletal bone mineral density (BMD) also declines, progressing through 
stages of “reduced” BMD, known as osteopenia, and “low” BMD known as 
osteoporosis [44, 59, 68]. Low muscle mass and low bone mineral density share similar 
risk factors, including older age, low activity levels and changed hormone profiles [136, 
138].  
 
Although it is possible to have low muscle mass without low BMD in older age and 
vice-versa, these conditions more often co-occur [266-269]. Direct interactions may 
link the changes affecting muscles with those of bone as muscle forces are transmitted 
to bones during physical activity to provide a growth stimulus. This regulation of 
muscle on bone is commonly known as the ‘mechanostat theory’ [4, 82, 88, 174], 
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explaining how high muscle mass is associated with higher BMD [83, 270] while, 
conversely, low muscle mass is associated with lower BMD [98, 271]. However, direct 
responses to loading are not the only possible mechanism of interaction between 
muscle and bones, since both respond to growth factors in the local milieu. Factors 
released by muscle or bone tissue might regulate growth or catabolic processes of the 
other tissue, evidencing bi-directional interactions and building substantially upon the 
mechanostat theory, which describes only effects of muscle on bone. 
 
Circulating factors have been associated with BMD amongst relatively healthy older 
men and women [272]. For instance, concentrations of DKK1, OPG and Sclerostin were 
higher in old than young adults, while OC was lower in old compared with young. 
DKK1, Sclerostin, OC and OPG were positively associated with BMD in older age [272]. 
These factors released by cells, including osteocytes, can regulate osteoblasts or 
osteoclasts during bone formation and resorption, but may also act on skeletal 
muscles and be associated with muscle mass in older age. For instance, Osteoclacin 
has been shown to influence muscle and bone cells [13, 189]. Diminishing Osteocalcin 
by gene knock-out or receptor knock-out leads to low exercise capacity [13, 190] and 
this is also the case when osteocalcin knock-out is restricted to osteoblasts [189] 
highlighting the importance of the bone-muscle cross-talk. Bone morphometric 
proteins (BMPs) are also involved in bone and muscle adaptations. BMPs are involved 
in limb bone patterning during development [273] but also have been shown to inhibit 
the myogenic process of muscle development, with chick limb bud cultures, and 
possibly transform the myoblasts to a chondrogenic fate, eventually forming cartilage 
[274]. Using mouse models, it has been shown the BMP-2 can induce bone formation 
whilst also up-regulating BMP receptors on muscle fibres causing muscle regeneration 
 91 
[275]. OPG has also been shown to interact with muscle, in particular OPG can 
regenerate muscle force within fast twitch fibres in muscle degenerative diseases, such 
as muscular dystrophy, using mice models. It also acts a regulator in vascular smooth 
muscle cells, acting as a down regulator of vascular calcification [276-279]. These 
studies demonstrate that muscle tissue responds to factors usually associated with 
bones. However, little is currently known about their association with muscle mass or 
changes with ageing in humans. 
 
The purpose of the present study was to investigate whether the selected circulating 
factors previously associated with bone, are related to whole body lean mass of young 
and older men and women. 
5.1.3 Materials and Methods 
5.1.3.1 Study Design 
The cross-sectional European multi-centre MYOAGE cohort consists of relatively 
healthy older men and women (aged 69 to 81 years) and young adults (aged 18-30 
years) [211] as shown in Table 8. The study was approved by ethics committees within 
each institute and written informed consent was obtained from all participants. 
Participants were recruited by advertisement in newspapers, the University of the 
Third Age and Association of Emerti. All measurements were performed according to 
standard operating procedures that had been unified at the study centres and data 
collection was ceased through December-March and July-August. Volunteers were 
excluded if: dependent living, unable to walk a distance of 250 m, presence of 
morbidity (such as neurologic disorders, metabolic diseases, rheumatic diseases, heart 
failure, severe chronic obstructive pulmonary disease and hemocoagulative 
syndromes), immobilization for one week during the last three months and 
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orthopaedic surgery during the last two years or still causing pain or functional 
limitations. The inclusion and exclusion criteria were designed to ensure the selection 
of relatively healthy participants and to minimize the confounding effect of 
comorbidity on sarcopenia [211] and we recorded the use of bisphosphonates, calcium 
and vitamin D supplements. The present study included 443 participants (Leiden, The 
Netherlands (young; n=35, old; n=75); Jyvaskyla, Finland (young; n=34, old; n=65); 
Tartu, Estonia (young; n=39, old; n=60), Paris, France (young; n=35, old; n=30) and 
Manchester, UK (young; n=28, old; n=42)) with complete BMD and bloods results. 
 
5.1.3.2 Dual-energy X-ray absorptiometry 
A whole body scan was performed using DXA while the participants lay supine, as 
previously reported [211] (The Netherlands: Hologic QDR 4500, version 12.4, Hologic 
Inc., Bedford, MA, USA; Finland: Lunar Prodigy, version en-Core 9.30; Estonia: Lunar 
Prodigy Advanced, version en-Core 10.51.006; France: Lunar Prodigy, version encore 
12.30; United Kingdom: Lunar Prodigy Advance, version enCore 10.50.086). A trained 
technician completed the daily equipment calibration and the DXA scans according to 
local and manufacturers’ quality control procedures. Participants wore a light cotton 
garment to reduce effects of clothing absorption on the scanning results. The whole-
body lean mass, fat mass and the WBMD were recorded after manual adjustment of 
the regions of interest carried out after the scan was complete. 
 
5.1.3.3 Blood sample analysis 
Blood samples were collected from a vein in the forearm into vacutainer EDTA tubes in 
the morning when participants were in a fasted state. Samples remained at room 
temperature for 15-30 min and were then centrifuged for 15 min at 2,000 *g at 4◦ C. 
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The plasma was collected and stored at -80◦C until analysis. Plasma concentrations of 
the selected analytes were determined in the research laboratory in Manchester, UK, 
using multiplex immunoassays (Millipore, Billerica, MA, USA).  The manufacturer 
instructions were followed and the magnetic bead panels quantified DKK1, OPG, OC, 
OPN and sclerostin using a 96-well plate after an overnight incubation. The sensitivity 
of each analyte was 1.4 (Dicckopf-1; DKK1), 1.9 (Osteoprotegrin; OPG), 68.5 
(Osteocalcin; OC), 37.7 (Osteopontin; OPN) and 31.1 (sclerostin) pg/mL. Samples were 
processed using a Luminex 200 Bioanalyser and protein concentrations were 
estimated using the xPONENT software (Luminex, v.3.1.871). TNF was sent to an 
external lab for analysis. 
 
5.1.3.4 Statistical analysis 
Participant descriptive characteristics (Table 1) were normally distributed, as assessed 
by Kolmogorov-Smirnov test, and are presented as mean ± standard error of the mean 
(SEM). Comparisons between age and gender were assessed using multivariate 
ANOVA. Relationships between height, whole body bone mineral density (WBMD), 
total body fat %, self-reported health and supplement use (independent variables) 
with whole body (WB) Lean mass (dependent variable) were first assessed with 
univariate correlations to identify the independent predictors of WB Lean mass. Then 
using bivariate Pearson’s product moment correlations were identified between the 
independent variables and WB Lean mass. Data for circulating factors were calculated 
as Z-scores per country as a standard deviation from the mean of the gender-matched 
young. Z-scores of WBMD, fat mass and height were also calculated for use in 
subsequent correlation and regression analysis. Spearman’s rho partial correlations 
were performed to assess relationships between the z-score WB Lean mass with z-
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scores of circulating factors using two models. The first model included adjustment for 
WBMD and height (accounting for the link between osteocytes and the circulating 
factors). The second model additionally accounted for differences that may be seen 
within the use of bisphosphonates, calcium or vitamin D supplements and self-
reported health as well as differences that may occur in height and WB Fat %. A 
stepwise multiple linear regression using the self-reported health and supplement use 
as well as z-scores for height, WB Fat %, WBMD and circulating factors was then used 
to evaluate which combination of the independent variables was associated with z-
score WB lean mass (dependent variable) in older adults and in young adults. Data was 
analysed using SPSS for Windows (v.21; IBM, USA) and significance accepted as p<0.05 
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5.1.4 Results 
Table 8. Participant Descriptive Characteristics 
 Old Young p-value 
 Men 
(n=129) 
Women 
(n=143) 
Men  
(n=82) 
Women 
(n=89) 
Age  Gender 
Age (years) 
 
74.6±0.3 74.0±0.3 23.6±0.3 23.2±0.3 <.0005 NS 
Height (m) 
 
1.74±0.01 1.61±0.01 1.81±0.01 1.67±0.01 <.0005 <.0005 
Body mass 
(kg) 
78.8±1.0 65.1±0.8 75.4±1.2 62.4±1.0 <.0005 .018 
BMI (kg/m2) 
 
25.8±0.3 25.2±0.3 23.1±0.3 22.4±0.3 .017 <.0005 
Body fat (kg) 
 
20.1±0.7 22.7±0.6 12.9±0.7 18.8±0.7 <.0005 <.0005 
Lean mass 
(kg) 
55.9±0.6 
 
40.2±0.5 
 
59.9±0.9 
 
41.4±0.6 
 
<.0005 <.0005 
Body fat (%) 
 
25.5±0.6 
 
34.6±0.6 
 
16.6±0.7 
 
29.6±0.7 
 
<.0005 <.0005 
Lean mass 
(%) 
71.9±0.6 
 
63.0±0.6 
 
79.8±0.7 
 
67.2±0.7 
 
<.0005 <.0005 
WBMD 
(g/cm2) 
1.19±0.01 
 
1.04±0.01  1.25±0.01 
 
1.15±0.01 
 
<.0005 .001 
Values are mean ± SEM. WBMD: whole-body bone mineral density. NS: No significant 
difference. 
 
Table 8 shows participant characteristics. Compared with young, the older adults were 
shorter, with higher total body and fat mass, but lower lean mass and WBMD. 
Compared with men, women were shorter, with lower total body and lean mass, lower 
WBMD, but higher body fat percentage.  There was a significant age * gender 
interaction for WBMD, (p<0.0005), but no age*gender interactions for any other 
characteristics. 
 
To identify associations, univariate correlations were assessed between BMI, 
supplement use, self-reported health, height, total body fat percentage and WBMD, all 
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with WB Lean mass as the dependent variable, were significantly correlated with WB 
Lean mass (BMI; r=0.347 p<.0005, Supplement use; r=-0.278 p<.0005, WBMD r=0.520 
p<.0005, Fat % r=-0.522 p<.0005, Self-reported health r=-0.164 p=0.008, Height 
r=0.868 p<.0005). For young, all were significantly correlated except for supplement 
use and self-reported health (BMI; r=0.416 p<.0005, Supplement use; r=0.065 p=0.402, 
WBMD; r=0.557 p<.0005, Fat %; r=-0.611 p<.0005, Self-reported health; r= -0.077 
p=0.322, Height; r=0.840 p<.0005). Based on these significances for old and young, all 
variables were therefore used as covariates subsequent multiple regression models. 
 
Table 9. The concentration of selected circulating factors in plasma in old and young, 
men and women.  
 Old Young p-value 
 Men Women Men Women Age Gender Age    x 
Gender 
DKK1 
(pg.mL-1) 
577.0 ± 
352-804 
575.3 ± 
346-864 
420.6± 
290-627 
494.3 ± 
284-703 
<0.0005 .942 .843 
OC   
(pg.mL-1) 
14160.5 ± 
9911-
18708 
16065.4 ± 
11073-
19933 
17581.1 ± 
13304-
21223 
16733.9 ± 
12013-
20715 
<0.0005 .880 .036 
OPG 
(pg.mL-1) 
319.2 ± 
229-419 
306.9 ± 
257-392 
159.4 ± 
114-193 
208.5 ± 
160-260 
<0.0005 <0.0005 <0.0005 
OPN 
(pg.mL-1) 
26590.1 ± 
17094-
38028 
21350.1 ± 
13971-
31255 
24822.5 ± 
16928-
35662 
20877.5 ± 
15937-
27777 
.700 .009 .184 
Sclerostin 
(pg.mL-1) 
5690.3 ± 
4348-
7556 
4147.6 ± 
3349-
5159 
3016.1 ± 
2079-
3932 
2366.0 ± 
1923-
3134 
<0.0005 <0.0005 0.034 
TNFα 
(pg.mL-1) 
1.79 ± 
1.53-2.09 
1.65 ± 
1.31-2.11 
1.47 ± 
1.10-1.77 
1.51 ± 
1.18-1.68 
<0.0005 .156 .242 
Values are median ± 25th – 75th percentiles.  
 
As described in the previous chapter, compared with young, older participants had 
higher concentrations of DKK1, OPG and sclerostin. Concentrations of OC were 
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significantly lower in old compared with young. OPN did not differ significantly 
between young and older participants. Compared with men, women had higher 
circulating concentrations of OPG, but lower OPN and sclerostin. There were no 
significant differences between men and women for DKK1 and OC. Age x gender 
interactions were found for OC, OPG and sclerostin (all p<0.05): the difference 
between young and old in OC, OPG and sclerostin was greater for men than it was for 
women. 
 
Table 10. Circulating factors associations with whole body lean mass, in old and young, 
men and women.  
Correlation 
With Z 
score WB 
lean mass 
All participants 
combined 
Old Young 
Adjusted 
models 
1 2 1 2 1 2 
DKK1 
(pg.mL-1) 
r=-0.099 
p= 0.601 
r=-0.247 
p=<.0005 
r=-0.191 
p=0.002 
r=-0.312 
p=<.0005 
r=0.017 
p=0.832 
r=-0.130 
p=0.098 
OC   
(pg.mL-1) 
r=-0.209 
p=0.267 
r=-0.183 
p=<.0005 
r=0.029 
p=0.649 
r=-0.175 
p=0.005 
r=0.022 
p=0.779 
r=-0.179 
p=0.023 
OPG 
(pg.mL-1) 
r=-0.059 
p=0.756 
r=-0.083 
p=<.0005 
r=-0.163 
p=0.009 
r=-0.170 
p=0.007 
r=-0.076 
p=0.337 
r=-0.204 
p=0.009 
OPN 
(pg.mL-1) 
r=-0.371 
p=0.043 
r=-0.111 
p=0.023 
r=-0.021 
p=0.735 
r=-0.144 
p=0.022 
r=-0.111 
p=0.162 
r=-0.147 
p=0.062 
Sclerostin 
(pg.mL-1) 
r=-0.004 
p=0.982 
r=-0.152 
p=0.002 
r=-0.266 
p=<.0005 
r=-0.235 
p=<.0005 
r=0.009 
p=0.908 
r=-0.248 
p=0.001 
TNFα 
(pg.mL-1) 
r=0.130 
p=0.495 
r=0.229 
p=<.0005 
r=-0.103 
p=0.113 
r=0.140 
p=0.030 
r=-0.079 
p=0.343 
r=-0.173 
p=0.037 
Data are shown as spearman’s rho. The circulating factors were log-transformed and 
then their z-scores calculated per country, compared to young values. The p values 
indicate the level of significance after statistical analysis. Results were adjusted for 1) Z 
WBMD and height; and 2) model 1 +Z fat %, self-reported health and supplement use. 
Significant relationships are highlighted using bold text.  
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Table 10 shows the associations between circulating bone regulatory factors and WB 
lean mass. When using z-scores of all variables and including all participants, while 
adjusting for WBMD and height (model 1), WB Lean mass was negatively associated 
only with OPN. All factors examined were negatively associated with WB Lean mass 
when additionally adjusting for WB fat %, self-reported health and supplement use 
(model 2), except for TNFα, which was positively associated.  
 
Negative associations between WB Lean mass and DKK1, OPG and Sclerostin were 
significant when restricting analyses to older participants for model 1. For model 2, all 
factors were negatively associated with WB lean mass in old, except for TNFα, which 
showed a positive association. When analysis was restricted to young participants, 
there were no significant associations for circulating factors and WB lean mass using 
model 1. However, in model 2, OPG, Sclerostin and TNFα were each negatively 
associated with WB lean mass (Table 10). 
 
Stepwise multiple linear regression was performed including Z-score WB Lean mass as 
the dependent variable and independent variables including: self-reported health and 
supplement use as well as the Z-scores for DKK1, OC, OPG, OPN and sclerostin, WB Fat 
%, WBMD and height. Results in the young showed OPG accounted for 12.8% of the 
variation in WB Lean mass (adjusted r2=0.118, p<0.0005), while OPG and height 
accounted for 18.6% of the variation in WB Lean mass (adjusted r2=0.186, p<0.0005). 
OPG, height and, WB Fat% accounted for 25.3% of the variation in WB Lean mass 
(adjusted r2=0.253, p<0.0005). OPG, height, WB Fat%, and DKK1 accounted for 28.9% 
of the variation in WB Lean mass (adjusted r2=0.289, p<0.0005). 
 
 99 
In the old, height alone accounted for 33.7% of the variation in WB Lean mass 
(adjusted r2=0.337, p<0.0005); height and OPG together accounted for 45.2% of the 
variation in WB Lean mass (adjusted r2=0.452, p<0.0005), while height, OPG and DKK1 
accounted for 49.4% of the variation in WB Lean mass (adjusted r2=0.494, p<0.0005). 
Height, OPG, DKK1 and WB Fat% accounted for 50.8% of the variation in WB Lean mass 
(adjusted r2=0.508, p<0.0005). Height, OPG, DKK1, WB Fat% and OC accounted for 
51.7% of variation in WB Lean mass (adjusted r2=0.517, p<0.0005). 
 
These results consistently identify OPG as associated with WB Lean mass, both in 
young and in older adults 
5.1.5 Discussion 
Whole body muscle mass declines markedly with advancing older age, progressing 
towards sarcopenia characterized by low muscle mass and physical function. The 
results of the present study suggest higher circulating levels of DKK1, OPG, OPN and 
sclerostin, and lower circulating levels of OC, are associated with lower whole body 
lean mass in older adults after considering body composition and stature. The 
association with OPG was most consistent, accounting for almost 12% of variation in 
whole-body lean mass of older adults and almost 13% for younger adults in 
multivariate analysis. 
 
OPG is a member of the tumor necrosis factor (TNF) super family, along with RANK 
(receptor activated nuclear-Kb) and RANKL (Ligand for RANK). This RANK/RANKL/OPG 
signalling pathway is a key regulator of vascular calcification [276] and bone 
formation/resorption [280, 281]. OPG is a soluble decoy receptor and can bind to 
RANKL preventing activation by RANK. The discovery of this pathway contributed to 
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the development of a bisphosphonate known as denosumab, that uses RANKL 
antagonists to halt the activity of osteoclasts and osteoblasts to help preserve bone 
mineral density [282], but actions may extend beyond bone, since OPG is also secreted 
by C2C12 skeletal myoblasts in culture [279], possibly to serve autocrine or paracrine 
functions. 
 
The present study is the first to associate circulating OPG levels with lean mass 
amongst young and older human adults, but there are several other indications of OPG 
effects on muscle using animal models and cell cultures. RANK regulates calcium 
storage, sarco-endoplasmic reticulum calcium ATP-ase (SERCA) activity as well as 
function of fast twitch muscle fibres, [278]. RANK is found on skeletal muscle cells and 
osteoclasts. Once RANKL binds it is able to activate Calcium signalling pathways as well 
as affecting the differentiation, activation and survival of osteoblasts. RANK deletion is 
able to protect from loss of specific muscle force, but not mass, in denervation. OPG 
immunoglobulin fragment complex (OPG-Fc) injections fully restored functional 
capacity of the extensor digitorum muscle in muscular dystrophy-induced mouse 
models [279].  
 
As a member of the TNF super family, it is possible that OPG interacts with TNF⍺. TNF⍺ 
is a pro-inflammatory cytokine and used to mark a chronic, low-grade systemic 
inflammation occurring in a range of conditions, including ageing where it was termed 
“inflamm-ageing” [283-285] associated with tissue damage [285]. TNF⍺ induces RANKL 
expression, activating the RANK signalling cascade and causing inflammation or cell 
apoptosis [286] usually in response to injury. The results of Table 9 show altered 
circulating levels of both TNF⍺ and OPG in older age and Table 10 shows both to be 
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independently associated with whole body lean mass.  Given both TNF⍺ and OPG are 
associated with WB Lean mass, possible interactions between these two factors may 
also occur, influencing lean mass. Others have reported TNF⍺ and OPG interactions 
[277-279], but none have previously demonstrated the associations with whole-body 
lean mass at the human level. When considered alongside previous research [272] 
these results identify OPG as a circulating factor released by bone and muscle cells 
with the potential to regulate muscle and bone function.  
 
In addition to the relationships for OPG and TNF⍺ discussed above, whole-body lean 
mass was inversely related to DKK1, OC, OPN and sclerostin during univariate analyses. 
However, only the relationship between DKK1 and lean mass remained significant 
after multivariate analysis. This is the first report, based on current literature, of 
associations between DKK1 and lean mass in older age. DKK1 has previously been 
shown to act as an antagonist regulating fibrosis formation after injury [287]. Some 
exercise studies have shown that circulating DKK1 levels decrease over the 
intervention period whilst muscular strength increases [288], an inverse relationship 
similar to these findings. Other studies have shown breakdown of muscle during ultra-
marathons as well as a decline in DKK1, resulting in less inhibition of osteoblast 
function [289]. DKK1 has also been shown the play a role in the upregulation of the 
calcification of vascular smooth muscle cells, in cell cultures exposed to high glucose, 
replicating diabetic muscle [290]. This highlights possible effects of DKK1 for muscle 
cells, identifying it as another candidate coordinating muscle-bone cross talk.  
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5.1.5.1 Strengths and limitations 
The strengths and limitations of this study are the same as those that are highlighted 
in Chapter 4, Section 4.1.5.2. Briefly, they include the cross-sectional study design 
which cannot reveal causal relationships; the study of relatively healthy participants 
limiting the findings to only those without mobility limitations of greater burden of 
disease. Another limitation of this work is that the measurement of circulating 
regulatory factors means that it was not possible to identify the originating cells 
releasing the factors into the circulation. Future studies should explore the inter 
relationship between OPG and TNF and their respective effects on skeletal muscle 
cells.  
 
5.1.5.2 Conclusion 
Sclerostin, DKK1, OPG and OC were inversely associated with WB Lean mass in older 
adults. The average WB Lean mass was lower in old than young and the circulating 
DKK1, OPG and sclerostin were higher in old than young. Multiple linear regression 
identified, in the old, Height, OPG, DKK1, WB Fat% and OC accounted for 51.7% of 
variation in WB Lean mass (adjusted r2=0.517, p<0.0005). Of these, OPG was most 
consistently associated with WB Lean mass. 
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6.1 Chapter 6: Human skeletal myoblast responses to tumour necrosis factor alpha 
exposure and the potential protective effects of osteoprotegrin. 
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6.1.1 Abstract 
Purpose; The pro-inflammatory cytokine TNF causes myoblast cell apoptosis in vitro. 
The present study was designed to investigate the potential protective effects of OPG 
against TNF exposure. 
Methods; Human myoblast cells were cultured with TNF alone, OPG alone and both 
molecules combined. Myoblast differentiation parameters including aspect ratio, 
fusion index (%) and myotube area (%) were calculated. OPG concentration was 
measured in cell supernatants and selected ‘myokines’ were measured from 
supernatants of myoblasts exposed to TNF. 
Results; Differentiation parameters showed a significantly greater proportion of 
differentiation when OPG was added to the cultured myoblasts before TNF 
(p<0.0001). ELISA showed significant secretion of OPG released from human myoblast 
cells, particularly during the first 24h of incubation (p=0.001), with an interaction 
effect found between TNF and time F;(15,24) 3.340, p=0.004. Other myokines; 
Osteonectin, Interleukin-6 (IL-6), Leukemia inhibitory factor (LIF) and Fatty acid binding 
protein (FABP) were also secreted from human myoblast cells as identified using 
multiplex. Interaction effects were seen for all four myokines; Osteonectin; F (15,24) 
7.45, p<.0005. LIF; F (15,24) 15.7, p<.0005. FABP3; (15,24) 14.5, p<.0005. IL-6 F (15,24) 
14.5, p<.0005.    
Conclusion; OPG may protect myoblasts against TNF exposure and may therefore be 
used as a therapeutic target for intervention against inflammation associated with 
ageing. 
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6.1.2 Introduction 
Chapter 5 has identified Sclerostin, Dickkopf-1, Osteoprotegrin and Osteocalcin to be 
associated with WB Lean mass, the same factors that were identified to be associated 
with whole body bone mineral density, as highlighted in Chapter 4. More specifically, 
Chapter 5 has shown Osteoprotegrin to be a consistent factor associated with whole 
body lean mass, having possible interactions with another circulating factor; tumor-
necrosis factor-alpha. Chapter 6 investigates this possible interaction effect, further, 
using human myoblast cells in culture, addressing the final objective. 
 
Previous research conducted [272], amongst others, has shown that loading (exercise) 
and molecules released from muscle and bone cells into the circulation can influence 
both BMD and muscle tissues [181, 291-293]. OPG and TNF were the two main 
factors found to be associated with whole body lean mass using our statistical models 
described in Chapter 5. The previous chapter also highlighted the interactions between 
OPG and TNF, by using one another as covariates within the association models. The 
association between TNF⍺ and lean mass was attenuated after accounting for OPG, 
but the relationship between OPG and lean mass remained after accounting for TNF⍺.  
 
OPG is a circulating factor associated with bone formation. RANKL is the receptor 
activator of NF-B ligand, RANK is the receptor activator of NF-B (RANK) and OPG is 
the soluble decoy receptor of RANKL. RANK, RANKL and OPG are all part of the tumor 
necrosis factor superfamily [294, 295]. RANKL is expressed on osteoblasts which can 
then bind RANK causing the formation of osteoclasts, initiating bone resorption. OPG is 
a decoy receptor for RANKL. This can prevent binding of RANK to its ligand, slowing 
down the process of bone resorption [296]. The proportion of RANKL to OPG must 
remain relatively balanced to maintain bone turnover [297]. There have been studies 
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to show OPG is associated with muscle using C2C12 cells in vitro. They have the ability 
to secrete OPG and an OPG-immunoglobulin fragment complex is able to reverse the 
effects of muscular dystrophy in mice [277-279]. This pathway also regulates the 
growth of vascular smooth muscle cells, as the OPG gene suppresses the calcification 
of these smooth muscle cells [276].  
 
Ageing also triggers a pro inflammatory response characterised by higher levels of 
circulating TNFα which is linked with a gradual decline in physical activity, presenting 
as low grade chronic inflammation [144]. Studies have shown that sarcopenia is 
accompanied by increased levels of inflammation factors, including TNFα and IL-6, and 
these factors have a catabolic effect over the long-term, accelerating muscle and bone 
tissue declines [134].  
 
TNFα has been shown to have detrimental effects on myoblast cells in vitro [17, 298-
301]. Using C2C12 muscle cell lines, incubation with TNF results in a total muscle 
protein loss.  Specifically the TNF binds to its targeted DNA sequence and causes 
degradation of I-B and NF-B, inducing skeletal muscle protein loss [300]. 
Furthermore, diaphragm muscles excised from mice overexpressing TNF have a 47% 
decrease in contractibility compared to that of control models. It is thought that this 
contractile dysfunction is a result of endocrine mediated oxidative stress [298]. Some 
human testing has identified TNF to be expressed when staining cardiac myocytes, of 
patients with cardiomyopathy. TNF is positively correlated with left ventricular 
volume and negatively correlated with left ventricular systolic function [301]. 
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The primary aim for this chapter was to identify if OPG protects against the effects of 
TNFα on human myoblasts in vitro. The hypothesis was (1) that OPG will be secreted 
from myoblasts cultured with TNFα, and (2) OPG protects myoblasts from apoptotic 
effects of TNFα. There were three main objectives. 
1. Identify the optimum concentration of TNFα and OPG to be used in culture 
with human myoblast cells 
2. Identify differences in differentiation parameters when culturing myoblasts 
with OPG and TNFα, when adding the factors to culture at different time points 
3. Using an ELISA and a multiplex kit, identify if human myoblasts secrete OPG 
and other myokines in response to culturing with TNFα.  
 
6.1.3 Materials and Methods 
 
6.1.3.1 Cell Culture 
 
One 25 year old (C25) non-commercial, immortalized Skeletal muscle cell-line was 
generated by using transduction with both telomerase-expressing and cyclin-
dependent kinase 4-expressing vectors [302]. This cell line was donated to the 
research group by previous collaborating partners at the Institute of Myology, Paris.  A 
frozen vial containing 1 ml of 1x106 cells each suspended in 90% fetal bovine serum 
and 10% dimethyl sulfoxide was thawed and transferred into a conical tube of 9 ml 
prepared complete growth media (GM) for proliferation (Table 1).  
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Growth Media (GM) Components (as per 500ml) Concentration 
Dulbecco’s Modified Eagles Media (DMEM) from Lonza 
(Nottingham, UK) 
60% (320ml) 
Medium 199 WITH Earle’s BSS from Lonza (Nottingham, UK) 20% (80ml) 
Heat inactivated fetal bovine serum (FBS) from Gibco 
(Loughborough, UK) 
20% (100ml) 
L-glutamine from Lonza (Nottingham, UK) 1% (5ml) 
Fetuin from fetal bovine serum from Sigma-Aldrich (Dorset, UK) 25ug.ml-1 
Recombinant human fibroblast growth factor-basic (FGFb) from 
Gibco (Loughborough, UK)  
0.5ng.ml-1 
Recombinant human epidermal growth factor (EGF) from Gibco 
(Loughborough, UK)  
5ng.ml-1 
Recombinant human hepatocyte growth factor (HGF) from Sino 
Biological Inc. (Suffolk, UK)  
2.5ug,ml-1 
Recombinant human insulin from Sigma-Aldrich (Dorset, UK)  5ug.ml-1 
Dexamethasone from Sigma-Aldrich (Dorset, UK)  0.2ug.ml-1 
Penstrip 10ug.ml-1 
Plasmocin 10ng.ml-1 
Table 11: Complete Growth Media for Skeletal Muscle cell proliferation. 
The 10 ml suspension of the 25-year-old cells (C25) was transferred into a T75 flask. 
The flask was incubated at 37°C with a 5% CO2 atmosphere until cell density reached 
80% confluence (percentage of area covered in an average field of view). When the 
flask was 80% confluent, GM (prepared as shown in Table 1) was aspirated from the 
flask and the cells washed twice with Dulbecco’s Phosphate Buffered Saline (DPBS) 
from Lonza (Nottingham, UK). The cells were then disassociated using 2 ml of 
TrypLETM Express Enzyme from Gibco (Loughborough, UK) incubated at 37°C in 5% 
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CO2 for 5 minutes. The 2 ml cell suspension was transferred into a conical tube and 
homogenized with 8 ml of GM. The cells were counted on a haemocytometer using 20 
μl of cell suspension and 20 μl of Trypan Blue Stain (0.4%) from Lonza (Nottingham, 
UK). Viable cells.ml-1 were calculated using the formula: Average number of live cells in 
one large corner square x dilution factor x 104.  
 
6.1.3.2 Objective 1 
Optimisation for the concentration of OPG and TNF 
C25 skeletal muscle cells were seeded at a concentration of 1.5x105 cell.ml-1 in GM in 
6-well plates pre- coated with a 0.5% gelatin solution. Cells were incubated for 24 
hours. Subsequently, GM was aspirated and the cells washed twice with DPBS. 
Differentiation media (DM; Table 2) was added to each well (2 ml) along with a 
concentration of OPG or TNFα at 5, 10, 15, 20 and 30 ng.ml-1. The plates were then 
incubated for 48 and 72h. Immunofluorescence microscopy was used to compare the 
differentiation parameters of both cell lines at 48 and 72h with different 
concentrations of OPG and TNFα (See Figure 1). At each time point DM was aspirated 
and cells washed twice with DPBS. Cells were fixed using 4% paraformaldehyde, 
incubated for 8 minutes at 21°C. Cells were washed thrice with DPBS then 
permeabilized using 1x Tris (0.5M) TBS containing (0.2% Triton X-100) for 30 min at 
room temperature. Cells were then blocked using 1x Tris (0.5M) and TBS containing 
(5% normal goat serum) for 60 mins, at room temperature. Then washed x3 with TBS. 
Perm/wash buffer was aspirated and the cell washed a final time with DPBS. Cells were 
then stained with 5 μg.ml-1 Texas Red®-X Phalloidin from Invitrogen (Paisley, UK), 5 
μg.ml-1 Anti-Myosin Heavy Chain Alexa Fluor® 488 from eBioscience (Hatfield, UK), and 
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2 ng.ml-1 4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI) from Sigma-Aldrich® 
(Dorset, UK). The stained cells were visualized using a The Leica DMI6000 B inverted 
microscope from Leica Microsystems (Milton Keynes, UK), for fluorescent microscopy. 
ImageJ was used to measure the differentiation parameters. Five random fields of view 
were assessed at 20x magnification.  
Differentiation Media (DM) components as per 500ml Concentration 
DMEM (glucose 4.5g.ml-1 &L-glutamate) from Lonza 
(Nottingham, UK) 
500ml (100%) 
Recombinant Human insulin from Sigma-Aldrich (Dorset, UK) 10g.ml-1 
L-glutamine from Lonza (Nottingham, UK) 1% (5ml) 
Penstrip 10g.ml-1 (5ml) 
Plasmocin 10ng.ml-1 
Table 12: Complete Differentiation Media for Skeletal Muscle cell proliferation. 
6.1.3.4 Statistical Analysis for Objective 1 
Data was normally distributed as assessed using the Kolmogrov-Smirnov test. For 
objective 1, a repeated measures ANOVA was used to test whether the two incubation 
periods (48 and 72 hours) had the same myotube area percentage at the different 
concentrations (0, 5, 10, 15, 20 and 25ng.ml-1 of OPG, and 0, 5, 10, 15, 20 and 30 ng.ml-
1 for TNF. All comparisons were made using SPPS v21. Significance was accepted at 
the p<0.05 level. Results are displayed in figure 1. 
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6.1.3.5 Objective 2  
Differentiation Parameters 
To achieve objective 2, three six-well plates were seeded with cells as described in 
section 6.1.3.1. The plates were incubated for 60h with TNF and OPG as shown in the 
schematic below. 
Plate 1; 
TNF at 0h, OPG at 24h TNF at 0h GM 
TNF at 0h, OPG at 24h TNF at 0h, OPG at 24h DM 
Plate 2; 
OPG at 0h, TNF at 24h OPG at 0h GM 
OPG at 0h, TNF at 24h OPG at 0h, TNF at 24h DM 
Plate 3; 
OPG and TNF at 0h OPG and TNF at 0h GM 
OPG and TNF at 0h OPG and TNF at 0h DM 
 
6.1.3.6 Statistical analysis for objective 2 
For this objective 2, a one way ANOVA, with LSD as a post Hoc test, was used to 
determine the difference between the mean the differentiation parameters, myotube 
area (%), fusion index (%) and the aspect ratio, at a pre-determined end-point of 60h 
incubation, between the different co-cultures described above. Myotube area 
represents the percentage of myotubes within the field of view, the fusion index 
represents the percentage of nuclei within the myotube compared to the percentage 
of nuceli within the whole field of view and the aspect ratio represents the ratio of the 
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length of myotube to the width of the myotube (i.e. the smaller the ratio the higher 
the level of differentiation). The level of significance was determined at p<0.05. Results 
are shown in Table 13 and Figure 6.2.  
 
 
6.1.3.7 Objective 3 
Co-culture with TNF for ELISA and multiplex 
Human myoblast cells were seeded and cultured as previously stated. When adding 
DM to the wells of each plate, TNF was added at a concentration of 30 ng.ml-1, as 
used following on from optimisation. Leaving one well as DM only. Two plates were 
replicated and the incubated for 24, 48, 72 and 96 hours. The supernatant of each well 
was collected, labelled and then stored at -80C until analysis was to be carried out. 
6.1.3.8 Concentration of OPG in human cell culture. 
The concentration of OPG was measured using an ab100617-Osteoprotegrin Human 
ELISA kit (Abcam, UK) and was carried out according to the manufacturer’s 
instructions. Reagents and standards were prepped according to the 
recommendations. 100l of each standard and sample was added to each well. The 
plate was then covered and incubated over night at 4 C with gentle shaking. The 
solution was then discarded and washed with wash solution four times. 100L of 
Biotinylated Osteoprotegrin Detection antibody was added to each well, which was 
then incubated for 1 hour at room temperature, with gentle shaking. This solution was 
then discarded, and the plate washed 4 times with wash solution. 100L of the HRP-
Streptavidin solution was added to each well, the plate was then covered and 
incubated at room temperature for 45 mins with gentle shaking. The solution was 
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discarded, and the plate washed four times. Finally, 100L of TMB one-step substrate 
reagent was added to each well, the plate was then covered and incubated for 30 mins 
at room temperature, with gentle shaking. Immediately after incubation 50L of stop 
solution was added to each well. The plate was then read at 450nm. 
The absorbance for standards, controls and samples was calculated. The standard 
curve was plotted with standard concentration on the x-axis and absorbance on the y-
axis. The best-fit straight line was drawn through the standard points and the using the 
regression equation for the best-fit straight line the concentration of OPG was 
calculated in pg.ml-1. 
6.1.3.9 Concentration of myokines in Human cell culture 
The concentration of the myokines were determined using a Multiplex immunoassay 
bead panel (Millipore, Billerica, MA, USA). The manufacturer instructions were 
followed and the magnetic bead panels quantified; Apelin, Fractalkine, BDNF, EPO, IL-
15, Myostatin, Irisin, FSTL, Oncostatin, FGF-21, Osteocrin, Osteonectin, LIF, FABP3 and 
IL-6, using a 96-well plate after an overnight incubation. The sensitivity of each analyte 
was 38ng.ml-1 (Osteonectin), 3pg.ml-1 (LIF), 6.5pg.ml-1 (FABP3), 0.6pg.ml-1 (IL-6), 
36pg.ml-1 (Apelin), 26 pg.ml-1 (Fractalkine), 3 pg.ml-1 (BDNF), 378 pg.ml-1 (EPO), 2 pg.ml-
1 (IL-15), 163 pg.ml-1 (Myostatin), 191 pg.ml-1 (Irisin), 548 pg.ml-1 (FSTL), 2 pg.ml-1 
(Oncostatin), 5 pg.ml-1 (FGF-21) and 44 pg.ml-1 (Osteocrin). Samples were processed 
using a Luminex 200 Bioanalyser and protein concentrations were estimated using the 
xPONENT software (Luminex, v.3.1.871). Apelin, Fractalkine, BDNF, EPO, IL-15, 
Myostatin, Irisin, FSTL, Oncostatin, FGF-21, Osteocrin were all below the level of 
detection and were not included in further analysis. 
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6.1.3.10 Statistical Analysis for Objective 3 
The third objective was to measure the expression of OPG and other myokines from 
cultured myoblasts after exposure to TNF. Univariate ANOVA was performed with 
time point and concentration of TNF as fixed factors and OPG concentration as the 
dependent variable. An interaction effect was found between TNF*Time, 
F;(15,24)3.3.40, p=0.004. Given this, simple main effects of the concentration of TNF 
(0 or 30ng.ml-1) with the concentration of OPG found within the supernatant were 
assessed per time point (24, 48, 72 and 96 hours). The effects of TNF concentration 
at each time point were evaluated with pairwise comparisons and LSD adjustments. 
Analysis was performed using SPSS Version 21 (SPSS, Chicago, IL) software and p<0.05 
was considered statistically significant. 
 
6.1.4 Results 
 
6.1.4.1 Objective1 
To investigate the actions of OPG human myoblast cell cultures were performed along 
with TNFα, a known cytokine that can be inhibited by OPG as a decoy receptor. 
To ensure optimal cell differentiation for studies using human recombinant OPG and 
TNFα, different concentrations (0, 5, 10, 15, 20, 25 ng.ml-1 for OPG and 0, 5, 10, 15, 20, 
30 ng.ml-1 for TNFα) were used concurrently in a 6 well plate lined with 0.5%  
gelatin. Staining procedure (as described in materials and methods) was carried out at 
either 48h or 72h. Phase contrast microscopy was used to assess a view at x20 
magnification and ImageJ software was used to process images and calculate myotube 
area percentage for each concentration at the two different time points. Results can 
be seen in Figure 6.1. 
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B.                                                                           C.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. A. Determining myoblast percentage with different concentrations of OPG. Myoblast area 
was calculated with 6 different concentrations of OPG after 48h and 72h of incubation. Data are 
mean±SEM taken from one x10 magnification image within the specified concentration well. B. Image 
taken at 72h incubation with 20ng.ml-1 of OPG. C. Image taken at 48h incubation with 20ng.ml-1 of OPG. 
 
Repeated measures ANOVA was performed to identify any significant differences 
between times and concentrations. No differences or interactions were found for 
TNFα or OPG at any of the different time points. When incubating with TNF α alone all 
myoblast cells died off. Given these results we chose to use 20ng.ml-1 for OPG [303, 
304] and 30ng.ml-1 for TNFα [17, 305] based on previous literature. 
 
 
0 100µm 0 100µm 
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6.1.4.2. Objective2 
Differentiation parameters highlighted significant differences between the co-cultures 
(Table 13 and Figure 6.2). Aspect Ratio; OPG and TNFα at 24h was significantly lower 
(greater differentiation) than TNFα and OPG at 24h and TNFα and OPG at the same 
time. There was no significant difference in aspect ratio between OPG and TNFα at 
24h, TNFα and OPG at 24h and TNFα and OPG together, albeit values were higher for 
culturing TNFα alone (Table 13).  OPG and TNFα at 24h showed a significantly greater 
fusion index (%), and myotube area (%) than TNFα and OPG at 24h, TNFα and OPG and 
TNFα only (p<0.0005). There was no significant difference in fusion index or myotube 
area between TNFα and OPG at 24h and, either, TNFα and OPG or TNFα. There was 
also no significant difference between TNFα and OPG or TNFα only for fusion index or 
myotube area. 
Table 13; Differentiation parameters for different co-cultures 
Co-Cultures Aspect Ratio Fusion Index (%) Myotube area (%) 
TNF_OPG at 24h1 16.5±2.06$ 8.85±0.66 0.74±0.07+” 
OPG_TNF at 24h2 7.70±0.41*+$ 77.5±3.81* 39.9±5.15*# 
TNF and OPG3 15.1±1.90$ 6.15±0.66+ 3.41±0.37+ 
TNF 4 10.9±5.45+ 10.5±0.31+ 1.01±0.13 
OPG5 8.72±0.33*#~ 68.2±0.50*#~ 32.7±0.73# 
GM6 10.8±2.05+$ 3.84±0.72+$ 0.16±0.01 
DM7 8.57±0.80*+#~$^ 50.7±3.54*+#~^ 25.2±7.68* 
Data are mean±SEM.*significantly different to 1, + significantly different to 2, #significantly different to3, 
~significantly different to 4, $significantly different to5, ^significantly different to 6, “significantly different 
to7. 
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Figure 6.2; Differentiation parameters calculated at 60h of incubation. Panel A; Graphs Top to Bottom represent differentiation 
parameters; significantly different at ***p<0.0001 and **p<0.01 to TNF_OPG AT 24h. Significantly different to OPG_TNF at 24h 
at +++ p<0.0005, significantly different to TNF and OPG at ###p<0.005, #p<0.05. Panel B represent; Top to bottom, 
immunohistochemistry staining for TNF_OPG at 24h, OPG_TNF at 24h, TNF and OPG, TNF only. Green shows differentiated 
myotubes, blue hows nuclei. TNFα was added at a concentration of 30ng.ml-1 and OPG was added at a concentration of 20ng.ml-1. 
Data are mean ± SE. 
 
0   100µm 
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6.1.4.3. Objective 3 
Human myoblast cells were cultured with the previously established (Objective 1) 
concentration of TNF (30 ng.ml-1) and with DM only. These cultures were ceased at 
24,48,72 and 96 hours. The various concentrations of OPG found within the 
supernatant of these cultures are displayed in Figure 6.3. An effect of TNF was found 
with univariate analysis F; (15,24) 4.931, p=0.003. There was also an interaction effect 
between TNF and time F;(15,24) 3.340, p=0.004. 
Simple main effects by pairwise comparison are displayed in Table 13. There was a 
significant difference at 24h for TNF compared with DM only (p=0.001). At 48h a 
significant difference of OPG secreted was found for TNF cultures compared with DM 
(p=0.003). At 72h, TNF cultures differed significantly, albeit a lower concentration, 
from DM cultures (p=0.020), but at 96h no significant difference between TNF and 
DM cultures was found. 
 
Figure 6.3; The percentage change of OPG concentration when cultured with a concentration of     
30ng.ml-1 of TNF compared to 0ng.ml-1 of TNF. Baseline is zero when cultured with Differentiation 
media only. Error bars display standard error of the mean. Significantly different to baseline (*p<0.05, 
**;p<0.01,***p<.0001). Two repeats for each culture were carried out. 
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Table 14; Simple main effects displayed for differences in concentration of OPG 
secreted when cultured with different concentrations of TNF at different time points. 
Data are mean ±SEM. 
 
As well as investigating the concentration of OPG released by myoblasts when 
incubated with TNF at 30ng.ml-1, a multiplex was used to identify selected myokines 
that may also be released in response to the culturing with TNF, compared with no 
TNF (DM only). It was found that osteonectin, LIF, IL-6 and FAPB3 showed significant 
changes.  Interaction effects were seen for all four myokines; Osteonectin; F (15,24) 
7.45, p<.0005. LIF; F (15,24) 15.7, p<.0005. FABP3; (15,24) 14.5, p<.0005. IL-6 F (15,24) 
14.5, p<.0005.  Pairwise comparison was used to identify simple main effects, between 
the concentration of TNF and the concentrations of the myokines released. The 
results are found in table 3 with significance shown at p<0.05. Osteonectin showed 
significant difference at 72h and 96h with TNF concentration of 30ng.ml-1 (p<0.020). 
LIF showed significant differences at all time points (p<0.004). FABP3 only showed a 
significant difference at 96h (p<0.0005). Finally, IL-6 showed significant differences at 
48 and 96h (p<0.0005). 
 
    95% Confidence 
Interval 
Time 
(Hours) 
TNF 
Concentration 
(ng.ml-1) 
OPG 
concentration 
(pg.ml-1) 
Significance p (Simple 
main effects compared 
to Ong.ml-1 of TNF) 
Lower 
Bound 
Upper 
Bound 
24 0 
30 
617±17.7 
877±10.2 
 
0.001 
521 
781 
712 
972 
48 0 
30 
641±6.36 
861±19.1 
 
0.003 
545 
765 
736 
956 
72 0 
30 
918±1.84 
755±2.73 
 
0.020 
822 
659 
1014 
851 
96 0 
30 
734±7.05 
703±14.6 
 
0.639 
638 
607 
829 
798 
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Table 15; Simple main effects displayed for differences in concentration of myokines secreted when cultured with different concentrations of TNF 
at different time points. Data are mean ±SEM 
      Significance 
(Simple main effects compared to 0ng.ml-1 of TNF) 
Time (Hours) TNF  
(ng.ml-1) 
Osteonectin (ng.ml-1) LIF 
(pg.ml-1) 
FABP3 
(pg.ml-1) 
IL-6 
(pg.ml-1) 
Osteonectin 
P value 
LIF 
P value 
FABP3 
P value 
IL-6 
P value 
24 0 
30 
427±57.5 
196±8.90 
0±0 
38±1.98 
169±14.6 
123±5.03 
0±0 
150±12.9 
 
0.066 
 
0.004 
 
0.960 
 
0.733 
48 0 
30 
203±0.08 
233±30.1 
0±0 
98±6.70 
944±48.8 
854±101 
3±0 
4082±985 
 
0.807 
 
<.0005 
 
0.923 
 
<.0005 
72 0 
30 
530±16.1 
132±2.63 
0±0 
41±4.41 
2308±236 
5153±555 
0±0 
821±5.43 
 
0.020 
 
0.002 
 
0.142 
 
0.071 
96 0 
30 
793±201 
127±0.14 
18±5.48 
70±26.9 
11720±1155 
6031±327 
6±0 
1868±293 
 
<.0005 
 
<.0005 
 
<.0005 
 
<.0005 
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6.1.5 Discussion 
The primary aim of this original research study was to identify if OPG protects against 
the effects of TNFα on human myoblasts in vitro. This was done through three main 
objectives stated in section 6.1.2. 
 
Optimisation experiments did not identify any differences between concentration of 
TNFα or OPG and the myotube area percentage. Previous literature was used as a 
guideline for concentrations to be used in further experiments [17, 305]. 
 
 Differentiation parameters, fusion index (%) and myotube area (%) were significantly 
greater when human myoblasts were subject to OPG adding TNF⍺ after 24 hours 
(Figure 6.2a), compared with myoblasts cultured with TNF⍺ adding OPG at 24h, TNF⍺ 
alone and when adding TNF⍺ and OPG at the same time. 
As shown in the images in Figure 6.2b, it is clear the see the large variation in 
differentiation in these different culture models. If TNF⍺ is added to the media on its 
own there are very few myotubes differentiated (less green illuminated in 
immunohistochemistry, figure 6.2b), whereas when adding OPG first and then adding 
TNF⍺ after 24h there is clearly a significantly greater amount of differentiation, as 
shown from our statistical analysis, figure 6.2a. From this data it is indicated that OPG 
may be providing an initial ‘protective’ mechanism if added to the media before TNF⍺. 
OPG has previously been shown to have protective mechanisms using C2C12 cells of 
mice with muscular dystrophy, an OPG immunoglobulin fragment complex can 
improve muscular force, up to 54%, and reduce levels of inflammation [279]. Previous 
literature has focused on C2C12 cells or mouse models, this experiment shows the 
benefits of OPG can also be applied to human muscle cells in vitro. 
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To investigate the mechanisms of OPG in response to TNF⍺ further co-culture models 
were used. It is known that OPG has been shown to be released from muscle cell 
cultures using C2C12 cells in response to immunoglobulin fragment complex [279], as 
stated previously. Here it is shown OPG is be released from human myoblast cells in 
culture in response to TNF⍺ (Table 14). There has been speculation as to how it is that 
these muscle cells respond to TNF⍺ in this protective manner and it has been assumed 
that the RANK/RANKL/OPG pathway is the key regulator. However, recent findings 
have shown this may not be the case [306]. Dystrophin/RANK double deficient mice, 
i.e. models that cannot stimulate through the RANK/RANK, pathway, are still able to 
respond to an OPG fragment complex and induce increases in muscular force [306]. 
This does not deny the fact that OPG is still able to protect against TNF⍺, a marker of 
inflammation that is associated with sarcopenia and bone ageing [134, 144, 146, 147]. 
These culture models would indicate that OPG, a well-known circulating bone marker  
[272, 294-296] is able to be released from human muscle in response to a marker of 
inflammation, which could therefore become a potential therapeutic target for ageing 
muscle. TNF also has a large influence in cardiomyopathy and causes decline in 
cardiac muscle function [298, 301], OPG could act as a protective role in the same way 
as shown here, making it a clear option for intervention.  
 
With the plates being cultured at different time points, it allows the pattern of OPG 
secretion to be seen, as shown in Figure 6.3. At 24h there is a significant increase 
compared to culturing with DM only. At 72h, a significant decrease, with 96h showing 
no significant change. This suggests that the majority of OPG is released during the first 
24 to 48h in response to TNF⍺, and then OPG secretion begins to decline due to, 
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perhaps, another factor, although this cannot be certain. Further investigation is 
needed to identify the specifically activated signaling pathways, at these different time 
points. 
 
Further analysis has shown other myokines are released from muscle in response to 
TNF⍺. Table 15 displays the findings of our multiplex analysis, highlighting four 
myokines to be measured in the supernatants of the culture models, described above. 
Osteonectin, Leukemia inhibitory factor (LIF), Fatty acid binding protein (FABP) and IL-6 
were shown to be released from the muscle at different time points.  
 
Osteonectin had the most significant differences at 96 h. Given that the majority of the 
changes in OPG happened during the first 24-48h, this could suggest that the 
Osteonectin is being taken up in response to the build-up of OPG, as there is a decline 
compared to baseline values. Osteonectin is a bone matrix glycoprotein that is 
abundantly expressed in bone [307]. Osteonectin deficient mice have shown to be 
severely osteopenic, highlighting that osteonectin is a positive regulator of bone 
formation [307], acting in a similar fashion to OPG [250]. It may be that Ostenectin is 
the secondary responder to OPG, taken up by the muscle in response to TNF⍺. The 
majority of FABP was also taken up at 96h, as there is a decline in concentration 
compared to baseline values. FABP’s comprise of a large number of 15kDa proteins 
and they facilitate the transport of long chain fatty acids across the plasma membrane 
[308]. Exercise training, combined with low glycemic diets have been shown to 
increase insulin sensitivity and fat utilization [309], allowing fat to be ultilised as fuel 
for the training. Here the FABP seems to be increased in response to the OPG 
production after 96h of incubation. This gives further evidence that FABP is another 
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key participant in bone-muscle cross talk, here responding once OPG secretion has 
significantly declined.  
 
LIF has shown significant differences at all time points. The secretion could, therefore, 
be in response to either OPG or TNF⍺. LIF is essential for embryo implantation in the 
mouse [310]. Its receptor (LIFR) has also been implicated to be involved the regulation 
of bone formation [307], through binding with Oncostatin M. There is little evidence 
available to show that LIF can be released from muscle in response to inflammation 
markers or circulating bone factors. Our findings show that LIF can be released from 
human muscle cells and another factor influencing bone-muscle cross talk. Finally, IL-6, 
showed the most prominent secretion at 48h and 96h. This fits with previous findings 
that show IL-6 to be released from muscle in response to exercise and inflammation 
[179, 182, 311].  
 
Further research should be directed to identify the signaling pathways that are 
activated within the muscle cells to secret OPG, in response to TNF⍺, along with LIF, 
Osteonectin, FABP and IL-6. As well as the signaling pathways, any interaction at the 
receptor level of TNF⍺ molecules would help to identify what these circulating factors 
do to the myoblast cells to protect the muscle cells from apoptotic effects of TNF⍺ its 
action. 
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7.1 Chapter 7: General Discussion 
The overarching aim of the PhD project was to provide novel insights into how exercise 
and circulating bone regulatory factors may influence both bone and muscle health 
within older age. This was addressed through four objectives: 
1. Investigate the relationship between BMD and lean mass in athletic older people, 
taking into account accelerometry data, the training age and type of athlete (sprint 
or endurance). 
2. Identify the circulating bone remodelling factors associated with BMD in healthy 
young and older adults.  
3. Identify the circulating bone remodelling factors associated with whole body lean 
mass in healthy young and older adults.  
4. Using the selected circulating factors identified in objective 2 and 3, investigate the 
responses of cultured human immortalised myoblasts after exposure to these 
factors. 
 
7.1.1 Overview  
Chapters 3-6 cover the original research carried out as part of this PhD, each 
addressing one of the objectives stated above, fulfilling the overall aim. 
 
Chapter 3, objective1, revolved around a sample of exceptionally athletic older people 
and non- active healthy old. Comparisons of bone health and muscle strength were 
made between those active and non-active, as well as within the active group, 
between sprinters and endurance. The main findings here showed that sprinters had a 
higher BMD at the hip and spine than those competing in endurance activity and those 
not competing at all. On some occasions those carrying out endurance activity have no 
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greater bone health than those not competing. The differences in BMD between 
groups could not be explained by muscle mass or function, further research is needed 
to investigate these changes. Further studies are required to identify to what extent 
discipline-specific advantages in BMD relate to pre-existing differences in skeletal 
health, or to variance in skeletal loading not captured in this study.   
 
Chapter 4, objective 2, aimed to identify any associations between the circulating 
factors; DKK1, FGF23, OC, OPG, OPN and sclerostin with whole body bone mineral 
(WBMD) density. It was found that Sclerostin, DKK1, OPG and OC were each positively 
associated with WBMD in older adults, despite the average WBMD being lower and 
circulating DKK1, OPG and sclerostin being higher in old than young. Multiple linear 
regression identified BMI, circulating sclerostin and whole-body lean mass as 
explaining, approximately, 14% of all variation on WBMD amongst older adults. This 
helped to refine the number of circulating factors that could be associated with both 
bone and muscle during ageing.  
 
Chapter 5, objective 3, was designed to investigate those circulating factors and how, 
this time, they may be associated with whole body Lean mass, as well as WBMD. The 
same statistical procedure was used to identify associations with WB Lean mass, as 
used in Chapter 4. It was identified that OPG accounted for 12% of the variation in WB 
Lean mass, in the old. Further to this, we were able to carry out additional analysis 
between OPG and TNF⍺. When using TNF⍺ as a covariate, OPG was significantly 
inversely correlated with WB Lean mass in both young and old. Whilst this chapter only 
represents statistical analysis, it confirmed two circulating factors, TNF⍺ and OPG, that 
can interact with one another and in doing so OPG may be able to interact between 
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muscle and bone and influence the age-related decline in muscle mass and bone 
strength. Thus, this leads into the final chapter where these two factors are 
investigated at the cellular level using human myoblast cells, Objective 4. 
 
In order to carry out cell culture models it was necessary to, first, find optimum 
concentrations of OPG and TNF⍺ that the cells could be seeded at, this was identified 
at 20ng.ml-1 for OPG and 30ng.ml-1 for TNF⍺. Once concentrations were confirmed, the 
human myoblast cells could be cultured with the two factors, adding OPG and TNF⍺ 
together and at varying time points. As shown in Chapter 6, Figure 6.2, there were 
clear differences between models used, with OPG showing to provide a “protective” 
mechanism against TNF⍺, allowing the myoblasts to differentiate, when OPG is added 
to the cultures before TNF⍺. As it was found here that some interaction was existing 
between the TNF⍺ and OPG at the muscular level, the next stage of experiments were 
carried out to identify if OPG was able to be secreted from the muscle cells in response 
to the TNF⍺. Using 30ng.ml-1 of TNF⍺ it was shown that the myoblast cells were able to 
secret OPG, in particular during the first 24h of incubation. Along with OPG other 
myokines were released; Osteonectin, LIF, FABP and IL-6. This chapter identified 
several molecules that are able to interact with both bone and muscle and in particular 
identified OPG as a potential therapeutic target against inflammation in older age.  
7.1.2 Summary of main findings 
The research carried out as part of this PhD has achieved the four objectives stated in 
section 2.2, addressing the overall aim; to investigate how exercise and circulating 
bone regulatory factors influence both bone and muscle health in older age. 
These findings confirm that sprinting can cause greater increases in bone mineral 
density compared to endurance training, in older age. Endurance training does not 
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seem to produce any benefits to bone mineral density of the hip and spine, compared 
with non-active controls. The gains in sprinters comparatively to endurance master 
athletes cannot be explained by impact counts, muscle power or body composition. 
Circulating factors play a clear role in the bone mineral density and muscle mass of 
older adults. These differences seen initially between sprinters and endurance athletes 
could possibly be explained by variations in circulating factors, brought about by the 
specific training regimes. TNF has been shown to have particularly detrimental 
effects during ageing and is associated with sarcopenia and chronic inflammation. It 
has been shown here that osteoprotegrin (OPG) can counter act these damaging 
effects of TNF. It may be, within sprint training, OPG levels are somewhat elevated 
allowing OPG to act as a decoy receptor to the TNF ligand. TNF, therefore, is unable 
to stimulate its inflammatory and apoptotic pathways, reducing its negative effects, 
resulting in a slowed rate of the loss of muscle mass and bone strength as age 
progresses. 
 
These findings add to current literature investigating exercise effects on bone in older 
age, identifying sprint training to have positive effects for the spine and hip, and that 
endurance running may not be the best exercise to slow the age-related loss of bone 
mass. Osteoprotegrein has been discovered to be a key factor that can influence both 
bone and muscle in older adults and can act in a protective mechanism from another 
factor TNF. Osteoprotegrin could be targeted for further therapeutic intervention to 
slow down the loss of bone and muscle mass during ageing, and reduce chronic 
inflammation normally associated with ageing. 
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7.1.3 Further studies and limitations 
Accelerometry data shown in Chapter 3 was not collected in the control population, if 
it were then a more comparable data set may have been better able to explain the 
differences in BMD between groups. The cross-sectional nature of the study limits 
assessment of causal relationships between type of sport and BMD due to possible 
uncontrolled confounders.  There was very little information about other factors 
potentially related to bone health, such as use of medications and nutrient intake 
including vitamin D. In addition, a detailed training log was not taken, so there may 
have been some additional information missed, highlighting differences in exposure to 
higher impacts between sprinters and endurance runners. Master athletes may not be 
representative of the general ageing population, they have been training for the 
majority of their lives and they have avoided the age associated diseases. It cannot be 
certain that their physical activity is the reason they have avoided these 
diseases/comorbidities or if they are genetically predisposed.  The findings in this 
chapter can only show the differences in BMD between sprinters and endurance 
master athletes. Longitudinal data collection is needed to be able to identify if 
sprinting in the general ageing population has the same effects on BMD, compared to 
endurance running, as shown in the master athletes   
 
The circulating levels of markers, may be influenced by release from non-bone cells, so 
it is not possible to determine the originating cell type. It is possible that altered renal 
function can affect the levels of the circulating factors, but markers of renal function 
were not included in the present study due to limitation of plasma sample quantity. A 
phantom was not used to calibrate the DXA scanners across sites and we did not adjust 
the results to derive “standardised” DXA values, as others have done for hip and femur 
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sites [264]. Instead, all study centres followed the local quality control procedures, 
including use of phantoms and daily calibration and the results were adjusted for 
country of testing to account for possible systematic differences.  
 
Within our cell culture models whilst we identified various factors that were released 
from the muscle it is not certain how they interact with the TNF⍺, OPG or at the 
cellular level of the muscle. Nor were we able to identify what was happening on the 
myoblast cells when OPG was added to the co cultures before TNF⍺ to then allow the 
myoblasts cells to differentiate and be protected from the normal apoptotic effects of 
TNF⍺. Future studies should look to identify the specific interactions and pathways 
that occur at the muscular level. OPG has been identified as a potential therapeutic 
target for intervention with muscle ageing, however, without translation into an 
animal model, it cannot be certain that the interactions we have seen in culture will 
also be those that are seen within animal models. Using knock out OPG mice the levels 
of TNF⍺ compared to controls would be able to show whether the interactions we 
have seen between OPG and TNF⍺ are true. 
 
7.1.4 Conclusion 
This original research has shown circulating factors to have an influence on both bone 
and muscle, in particular OPG and TNF⍺. Muscle is able to secret OPG in response to 
TNF⍺ as well as Osteonectin, LIF, FABP and IL-6, that are released as a response to 
TNF⍺ and/or OPG. During ageing these factors could influence both bone and muscle 
deterioration. If these factors are further investigated they could become therapeutic 
targets of intervention to reduce the loss of bone strength and muscle mass during 
ageing. The most appropriate exercise regime suggested for ageing has not been well 
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defined, however, it has been shown, within this thesis, that sprinting, in master 
athlete, has more beneficial effects to bone health than endurance exercise and this 
should be taken into account when prescribing exercises for the elderly to slow down 
the effects of ageing on muscle and bone. The research conducted will contribute to 
the understanding of muscle and bone loss throughout older age and how these two 
organs may interact through circulating factors.
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7.3. Appendix 
 
Author Year Journal Intro Measurements Intervention Conclusion 
Cunha et al  2018 Journal of 
Sport Science 
Effects of Resistance 
Training with 1 or 3 sets of 
exercise on 
osteosarcopenia obesity 
older women 
62 older women, aged 68, 
12 weeks RT program 
2 training groups 
performed 1 or 3 sets of 
resistance exercises 3 times 
weekly and control group. 
Measured muscle mass and 
bone with DXA.  
No difference between 
training groups but 
Training groups showed a 
greater increase in muscle 
mass than controls. No 
effect on BMD between 
three groups.  
Overall higher positive 
change of Z scores in 3 set 
training group. 
Beavers et 
al 
2017 J Gerontol A 
Bio Sci Med 
Sci 
To examine the effect of 
exercise during weight loss 
on hip and spine BMD, in 
overweight and obese 
older adults 
Two, 5 month Randomised 
controlled trials, Calorie 
restriction with either 
aerobic or resistance 
training.  
123 adults ages 69yrs- 67% 
female. Resistance training 
n=60 and aerobic N=63.  
Resistance program 
involved 3 days per week of 
8 body exercises, 3 sets of 
10 reps at 70% 1RM, 
Aerobic training involved 
treadmill walking for 30 
mins at 65-70% max hr. 
Measured BMD with DXA 
at baseline and 5 months 
Total hip and femoral 
neck BMD was unchanged 
in the resistance training 
group and decreased in 
the aerobic training 
group. 
Duckham et 
al 
2015 Age and 
Ageing 
To evaluate the effects of 
home (Otago Exercise 
Programme, OEP) and 
group (Falls exercise 
management, FEM) falls 
prevention exercise 
programs relative to usual 
care in older people 
N=319 men and women 
aged 72yrs. Randomised 
into OEP, FEM or usual 
care, BMD and BMC and 
structural properties 
measured before and after 
24 weeks of intervention 
OEP group completed 58 
mins per week of home 
exercise while the FEM 
completed 39 and 30 min 
per week of group and 
home exercise. For 24 
weeks 
No difference between 
groups in femoral neck 
BMD, or BMC at other 
skeletal sites. Exercise 
may need to exert higher 
strains for longer. 
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Elsisi et al 2015 Clinical 
Intervention 
Aging 
Compare the response of 
BMC and BMD in elderly 
women to low frequency 
low plus magnetic field or 
circuit weight training 
(CWT) 
12 weeks of intervention. 
N=30 aged 60-70 yrs. 
Randomly assigned to 
magnetic field or CWT. 
12 Weeks of intervention, 3 
times per week. Measured 
BMD and BMC of lumbar 
spine, femoral neck and 
trochanter 
Both interventions 
showed statistically 
significant increases but 
Magnetic field showed 
slightly greater increase 
Rantalainen 
et al  
2011 Eur J Applied 
Physiology 
To identify the effects of bi 
lateral hopping on bone 
markers 
12 week bilateral hopping 
on balls of the feet. 25 
men aged 72, assigned to 
control group or 
intervention group. 
Subjects were tested in the 
lab three times per week 
for 12 weeks, conducting 
the bilateral hopping 5-7 
times in sets of 10 seconds. 
Sets were performed at 7—
90% intensity. 
Bone markers, CTx Cicp 
bALP did not change from 
base line to 12 weeks in 
either groups 
Marques et 
al 
2011 Calcified 
Tissue 
International 
Examine the effects of 
exercise against bone 
induced weakness 
8 month multicomponent 
training with weight 
bearing exercises on BMD. 
N= 30 in exercise group 
and 30 in control group. 
Training was performed for 
60 mins 2x per week. 
Involved 10 min of warm 
up activities, 15 min of 
weight bearing exercises, 
10 min muscular 
endurance, 10 min of 
balance, 10 min agility and 
5 min of stretching. Carried 
out for 8 months 
Femoral neck had an 
increase of 2.8% BMD 
Sakai et al  2010 J Bone 
Mineral 
Metabolism 
To test the effect of 
unipedal standing exercise 
on BMD of the hip in post 
menopausal women 
N=94 Mean age 68 yrs, 
randomly assigned to 
exercise or control group. 
BMD of hip measured with 
DXA. 
Exercise group performed 
the exercise three times a 
day for 6 months, with eyes 
open the participant was 
required to stand on one 
leg for one minute then the 
other leg= one set. One set 
was performed in the 
morning, noon and 
afternoon. 
Percentages changes in 
the hip BMD between 
groups did not differ. 
Effects of exercise on 
BMD did show an effect 
only on participants over 
age 70 yrs . 
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Bocalini et 
al  
2009 J Aging 
Health 
Evaluate the effects of 
strength training on BMD 
of post menopausal 
women without Hormone 
replacement therapy 
Subjects were randomized 
into training or no training 
groups. 
24 weeks of strength 
training sessions three 
times per week . Measured 
BMD of lumbar spine and 
femoral neck 
Demineralisation 
percentage was higher in 
the un trained group than 
trainer group, training 
attenuated the loss of 
BMD in post menopausal 
women. 
Tolomio et 
al 
2008 J Phys Act 
Health 
Evaluate the effects on 
bone tissue and muscular 
strength of short term 
exercise program in post 
menopausal women 
N=49 osteopenic/ 
osteoporotic women.  
Bone assessed by 
phalangeal quantitative 
osteosonography  
Two groups exercise and 
control group. Supervised 
20-week physical activity 
program that included 
aerobic, balance and 
strength training. 
After training period, all 
bone parameters 
significantly improved in 
exercise group (p<0.05). 
No sig changes in control 
group. 
Woo et al 2007 Age Ageing Investigate the beneficial 
role of exercise in 
improving bone mineral 
density in elderly 
community dwelling 
participants 
N=180 Subjects 90 men 90 
women aged 65-74 yrs old 
12 months. Subjects 
assigned to participate in 
Thai Chi or resistance 
training 3 times a week or 
no training. BMD was 
measured at baseline 6 
months and 12 months 
In women both the Thai 
Chi and resistance 
training had moderate 
lower loss of hip BMD 
compared to controls. No 
effects found in men. 
 
Table 16; A systematic review of bone and exercise in the old. The literature was systematically reviewed using the search engine PubMed. The words and 
descriptors used for the data search were (Ageing or aging) AND (Bone) AND (Sport or exercise or Physical activity). The search was refined to include only 
publications within the last 20 years, the studies being randomised controlled trials (RCT) or Observational studies, participants aged 65 years or over and human 
studies only. The search returned a total of 72 papers. Out of the 72 papers returned, a total of 10 studies were appropriate for the systematic review because they 
described direct effects of exercise on bone. 
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Author Year Journal Intro Measurements Intervention Conclusion 
Fielding et 
al 
2017 PLoS One To understand the 
effect of Physical 
activity on changes in 
physical function and 
the onset of major 
mobility disability. 
Lifestyle Interventions 
and Independence for 
Elders Study (LIFE) 
Multi centre ranomised 
control trial followed for 
2.6 yrs average. 1635 
sedentary men and 
women aged 70-89 yrs. 
Randomised to a structured 
moderate intensity walking, 
resistance and flexibility 
physical activity programme. 
Physical activity assessed by 
7 day accelerometry and self 
report at baseline and 24 
months. Outcomes included 
400m gait speed, short 
physical performance battery 
test and onset of disability. 
Small changes in physical 
activity improved 400 m gait 
speed and SPPB scores, 
which are used as indicators 
of frailty 
Ossowski 
et al  
2016 Clinc Interv 
Aging 
Evaluate the impact of 
Nordic walking training 
on skeletal muscle 
index, muscle strength, 
functional mobility and 
functional performance 
in women with low 
bone mass 
Participants were women 
aged 63-79 years with 
osteoporosis or 
osteopenia. 
Measurements taken with 
bioimpedance body 
analyser and muscle 
dynamometer. 
Randomly assigned to 
control group or activity 
group. The activity group 
carried out the nordiac 
walking 3 times a week for 
60 mins each session for 12 
weeks. Measured at baseline 
at 12 weeks 
Skeletal muscle mass, index 
and strength index of the 
knee extensor and flexor, all 
showed significant 
improvements. No change in 
the hang grip muscle 
strength or in the control 
group. 
Landi et al  2016 BMJ Open Evaluate the effect of 
sarcopenia on all cause 
mortality and the 
interaction among 
muscle loss, physical 
function impairment 
and multimorbidity on 
mortality risk over 10 
years in community 
dwellers  
All people within Sirente, 
Italy area n=364 aged 80 
yrs+. Measured all cause 
mortality over 10 yrs, 
impact of physical 
function impairment asses 
using  Short physical 
performance batter and 
multi morbidity on 10 
year mortality risk 
Sarcopenia was identified in 
103 participants. 253 deaths 
recorded in 10years, 10 
sarcopenic, 162 non 
sarcopenic. Of those, low 
physical performance levels 
had a greater mortality rates.  
Physical function impairment 
is predictive of mortality in 
this region. In sarcopenic 
older persons, interventions 
to reduce functional decline 
may reduce mortality rates. 
Mijnarends 
DM 
2016 Age and 
Ageing 
Physical activity may 
slow the rate of muscle 
loss and the incidence 
People within Reykavik 
Area n=2309 Aged 66-
93yrs old. Sarcopenia was 
n/a Sarcopenia at baseline was 
7.3% and 16.8 % at follow 
up. Those reporting higher 
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of sarcopenia. The aim 
was to examine  the 
association of Physical 
activity with sarcopenia 
over 5 years.  
identified using muscle 
mass, grip strength and 
gait speed. Amount of 
activity was assessed by 
self reported 
questionnaire.  
levels of physical actvity had 
significantly lower likelihood 
of sarcopenia. 
Nunes et al 2016 Age (Dordr) Evaluated the effect of 
resistance training 
volume on muscular 
strength and on 
indicators of abdominal 
adiposity in post 
menopausal women 
Muscle strength was 
measured and indicators 
of abdominal adiposity. 
No difference at baseline 
between groups 
N=32 average age 61yrs.  11 
in control group doing no 
exercise, 10 in low volume 
resistance training group and 
11 in high volume resistance 
training group. 8 exercises 
were performed at 70% of 1 
rm 3 times a week. For 16 
weeks 
In both trained groups 
showed increase in muscular 
strength and fat % reduction 
after intervention.  Some 
differences between trained 
groups in indictors of 
adiposity 
Zdzieblik et 
al 
2015 Br J Nutr Protein 
supplementation in 
combination with 
resistance training may 
increase muscle mass 
and strength in elderly 
subjects 
53 male subjects aged 
72.2 yrs. With sarcopenia 
completed as a 
randomized controlled 
study. Measured FFM FM 
and bone mass before and 
after intervention with 
DXA. Isometric quad 
strength was determined 
with standardized one leg 
stabilization test 
12 week guided resistance 
training programme with 
here sessions a week. 
Supplemented either with 
collagen or a placebo.  
Fat free mass and bone mass 
showed significant changes, 
Higher isometric quad 
strength all in group taking 
collagen supplementation 
Lauseen et 
al 
2015 J Am 
Geriatric 
Society 
Progressive resistance 
exercise is used in 
patients to improve 
muscular strength and 
physical activity in older 
adults, but it is 
unknown if this will 
improve physical 
function. 
Measure changes in 
physical function before 
and after 6 month 
progressive resistance 
exercise 
Community dwelling older 
adults aged 70-85yrs, 6 
month programme, Physical 
activity was measured with 
an activity monitor, physical 
function was assessed using 
short physical performance 
battery and repeated chair 
rise, stair climb and the 
400m walk test. The 
There were significant 
improvements in all 
measures of physical 
function from baseline to six 
months, no change in 
physical activity from 
baseline to 6 month . 
Other factors need to be 
targeted to improve physical 
activity 
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resistance training was done 
3 times a week, intensity 
progressed from two sets of 
10 reps at 80% of 1RM to 
three sets of 12.  Measured 
at baseline to 6 months. 
Reid et al 2015 J Gerontol A 
Biol Sci Med 
Sci 
We compared two 
different lower 
extremity power 
training interventions 
on changes in muscle 
power, physical 
performance, 
neuromuscular 
activation and muscle 
CSA in mobility limited 
older adults. 
52 subjects aged 78yrs.  16 weeks of progressively 
high velocity resistance 
training or high external 
resistance training. Two 
times a week for both groups 
Completing leg and knee 
extension exercises at max 
velocity. 
Improvements in 
neuromuscular activation, 
short physical performance 
battery and leg extensor. 
There were no significant 
between group differences.  
Shahar et 
al 
2013 Clinc Interv 
Aging 
To determine the 
effectiveness of 
exercise intervention 
and protein 
supplementation alone 
or in combination  
65 sarcopenic elderly 
participants aged 60-
74yrs. Assigned to control 
group, exercise group, 
protein supplementation 
or a combination. 
60 mins of exercises twice a 
week for 12 weeks 
The exercise programme 
was to found muscle 
strength and body 
composition, while protein 
supplementation reduced 
body weight and increased 
upper body strength among 
sarcopenic elderly. 
Hanson et 
al 
2009 J Strength 
and 
Conditioning 
To investigate the 
effects of strength 
training on physical 
function and the 
influence of strength, 
power, muscle volume 
and body composition 
on physical function. 
Healthy inactive adults 
aged 65 years and older. 
Underwent strength, 
power, total body 
composition and physical 
function testing before 
and after 22 weeks of 
strength training. 
10 week unilateral strength 
program using untrained leg 
as an internal control 
preceded 12 weeks of whole 
body strength training. 
Strength, power and fat free 
mass increased significantly 
with strength training in 
overall group. Women 
improved in walking 
whereas men improved in 
stair climb. Strength training 
improves functional tasks 
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Harber et 
al 
2009 Am J Physiol 
Regul Integr 
Comp Physiol 
To assess the influence 
of aerobic training on 
muscle size and 
function.  
12 week cycle ergometer 
training. Muscle volume 
measured by MRI. Muscle 
biopsies taken to 
determine size and 
contractile properties of 
slow and fast twitch 
fibres.  
12 week cycle ergometer 
training, 20-45 mins of 3 or 4 
sessions per week 
Aerobic training inc type 1 
fibre size. And type 1 peak 
power was elevated, while 
type 1 unaltered in size and 
power. Indicate that aerobic 
training improves muscle 
function through remodeling 
contractile properties at 
myofiber level. 
Raue et al  2009 J Appl Physiol To assess single muscle 
fibre contractile 
function and whole 
muscle characteristics 
before and after 12 
weeks oh high intensity 
resistance training. In 
very old women, aged 
85+ 
Young women acted as a 
control group. Whole 
muscle size using CT and 
strength by 1 rep max 
were asses before and 
after training. 
12 weeks progressive 
resistance training 
programme, assessed size, 
peak force, velocity and 
power on VL MHC 1 and 11 
type fibres. Training sessions 
were 2-3 times per week. 
1 rep max increased in old 
and young, no increase in 
thigh muscle csa in old. Type 
two fibres improved in size, 
peak force and power but no 
change in type 1 fibres. No 
changes in MHC type 1 or 
type 2 in the older women, 
shows the old women have a 
blunted response to 
resistance training at muscle 
and cellular level 
Reid et al  2008 Aging Clin 
Exp Res 
Investigate whether 
high velocity high power 
training improved lower 
extremity muscle power 
and quality in 
functionally limited 
elders greater than slow 
velocity resistance 
training 
N=57 Adults aged 74yrs 
Randomised into power, 
strength or control 
groups. Outcome 
measures include 1RM 
strength and peak power. 
Total leg lean mass was 
used to determine specific 
strength and specific PP. 
Training performed 3 times 
per week for 12 weeks, 
subjects performed three 
sets of double leg press knee 
extension exercises at 70% of 
1rm 
Peak power and specific 
peak power increased 
similarly from baseline in 
power and strength 
compared to controls. Gains 
in leg press peak power 
were greater in power than 
other groups. Total leg lean 
mass didn’t change in any 
group 
Table 17; A systematic review of muscle and exercise in the old. The following section of the review has been conducted as a systematic review, using the search 
engine PubMed. The words and descriptors used for the data search were (Ageing or aging) AND (Sarcopenia) AND (Sport or exercise or Physical activity). The search 
was refined to inclusion with publication within the last 20 years, the studies being randomised controlled trials or Observational studies and including participants 
aged 65+. This search produced 705 papers. Due to the large number for a small section within a review the search was further refined to include those with free full 
text. This search returned 254 papers, 20 of which were suitable for inclusion in the systematic review.  
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